Author: "Andriulli, A" / Topic: gastroenterology - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Andriulli, A"' showing total 413 results

Start Over Author "Andriulli, A" Topic gastroenterology

413 results on '"Andriulli, A"'

1. The specialty of gastroenterology: between a past of excellence and a somewhat uncertain future.

Author: Andriulli A
Subjects: Gastroenterology education, Health Services Accessibility, Humans, Italy, Minimally Invasive Surgical Procedures trends, Endoscopy, Gastrointestinal trends, Forecasting, Gastroenterology trends
Published: 2010
Full Text: View/download PDF

2. First do no harm: power, oppression, and violence of liver biopsy.

Author: Andriulli A, Annese V, Facciorusso D, and Giacobbe A
Subjects: Hippocratic Oath, Humans, Biopsy adverse effects, Gastroenterology standards, Liver pathology, Liver Diseases pathology
Published: 2003
Full Text: View/download PDF

3. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists?

Author: Musto P, Dell'Olio M, Carotenuto M, Mangia A, and Andriulli A
Subjects: Adult, Aged, Antiviral Agents therapeutic use, Comorbidity, Hepatitis C epidemiology, Hepatitis C therapy, Hepatitis C Antibodies blood, Humans, Immunologic Factors therapeutic use, Interferons therapeutic use, Middle Aged, Paraproteinemias epidemiology, Paraproteinemias therapy, Paraproteinemias virology, Patient Care Team, Prevalence, Seroepidemiologic Studies, Gastroenterology, Hematology, Hepatitis C complications, Paraproteinemias etiology
Published: 1996

4. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Author: S. Abiru, John F. Dillon, Yasuhiro Miyake, Piero Portincasa, Giancarlo Spinzi, R. Harvey, T. Ngatchu, Agostino Colli, M. Taniai, K. Flahive, Masanori Abe, B. Hoeroldt, S. Holder, Howard Curtis, María Isabel Colombo, C. MacNicol, Gang Xie, Andrew Chilton, H. Hussaini, Cristina Rigamonti, M. Kato, Shintaro Yagi, G. Abouda, D. Tyrer, Chris D. Evans, Christopher I. Amos, K. Koss, Kazuaki Chayama, P. Premchand, K. Migita, Simon Panter, Marco Marzioni, Silvia Colombo, Konstantinos N. Lazaridis, M. Yagura, Ashley Brown, D. Gocher, Domenico Alvaro, K. Murata, Mark Wright, Piero Luigi Almasio, C. Healey, A. Ciaccio, N. Wheatley, Vincenzo Cardinale, T. Delahooke, Chiara Milani, T. Shewan, W. Stableforth, S. Levi, Mark L. Green, James V. Jones, Y. Baird, Aftab Ala, Burroughs Ak, D. Williams, K. Ario, P. Sanghi, Hemant Gupta, P. Southern, L. Farrington, M. Hamilton, Andrew D. Higham, I. Yabuuchi, H. Yatsuhashi, Lorenzo Morini, T. Yamamoto, Douglas Thorburn, M. Carnahan, N. Nishida, Susan Slininger, M. Koga, K. Honda, Annarosa Floreani, Andrew Douglass, K. Netherton, M. Yasunami, Hirohito Tsubouchi, F. Donato, K. Walker, U. Shmueli, Paolo Muratori, Ray Mathew, J. Maiden, E. Dungca, Subramaniam Ramakrishnan, S. Vyas, Helen Sweeting, Subrata Saha, T. Komeda, T. Komatsu, H. J. Lee, Maria Consiglia Bragazzi, T. Komura, C. Thomas, C. Shallcross, C. Duggan, J. Kordula, F. Muscariu, Lourdes Cumlat, Imran Patanwala, Giulia Cardamone, L. Morgan, J. Brighton, Masao Honda, H. Nakamura, David Jones, Raj Srirajaskanthan, M. E. Gershwin, T. Muro, L. Stafford, N. Fukushima, Graham P. Butcher, Andrea Crosignani, George Lipscomb, K. Hirata, Y. Nagaoki, S. Mann, Paul G. Richardson, David A Elphick, M. Mupudzi, Y. Ohara, E. Grieve, Gayle Clifford, Claudio Tiribelli, M. Quinn, G. Van Duyvenvoorde, E. Archer, Tatsuki Ichikawa, J. Maltby, T. Arinaga-Hino, Simon Williams, A. King, Yasuni Nakanuma, H. Doyle, A. Brind, Nora Cazzagon, H. Ota, Daphne D’Amato, K. Hogben, H. Wooldridge, J. Wilkins, Shuichi Kaneko, L. Hankey, Gordon Wood, Andrew Fraser, K. Martin, A. Naqvi, M. Ninkovic, M. Patel, Yoshihiko Maehara, Kapil Kapur, I. Amey, Vincenza Calvaruso, Kenichi Harada, T. Yamashita, James Neuberger, N. Taylor, T. Lee, J. Featherstone, C. Lawlor, K. Seward, Satoshi Yamagiwa, Andrea Galli, L. Tan, Kentaro Kikuchi, K. Furuta, Mark A. Ainsworth, Hiromasa Ohira, Esther Unitt, Yosuke Kawai, N. Lancaster, D. Simpson, R. Shidrawi, I. Salam, A.J. Bell, Pietro Andreone, J. Ishida, Voi Shim Wong, N Fisher, Andrew C. Douds, R. Penn, Matthew Foxton, A. Watson, Andrew Mason, S. Walsh, Hiromi Ishibashi, Daniel M. Forton, Giovanni Casella, H. Takaki, K. Yamauchi, Pietro Lampertico, Osamu Yokosuka, M. Koda, M. Davies, H. Mitchison, P. Gyawali, G. Bird, M. Hughes, L. Jones, C. Hamilton, A. Hynes, R. Galaska, Fabio Marra, Debasish Das, C. Cowley, A. Fouracres, Yasuhiko Sugawara, E. Mita, T. Saoshiro, Akinobu Taketomi, Robert P. Myers, R. Przemioslo, F. Wright, L. Hobson, L. Currie, J. Allison, J. Hails, Noriyo Yamashiki, Massimo Zuin, C. Grimley, Alessio Gerussi, S. Besley, Stefano Duga, A. Piotrowicz, H. Kouno, L. Dali-kemmery, H. Sakai, M. Mizokami, Stefano Fagiuoli, Amy Davis, Pier Maria Battezzati, Masao Nagasaki, Luigi Muratori, A. Mori, S. Desmennu, S. Jones, R. Abrahams, Keith George, F. Makita, J. Brown, D. Gorard, Satoru Joshita, M. Mills, Pierluigi Toniutto, S. Campbell, J. Butterworth, S. Dyer, Filomena Morisco, Norihiro Kokudo, T. Yapp, C. Shorrock, Floriano Rosina, E. Walker, Shinji Uemoto, H. Takahashi, Simon M. Rushbrook, K. Amor, E. Marshall, J. Browning, S. Batham, Luca Fabris, Paul R. Banim, Meenakshi Narain, M. Harada, Dermot Gleeson, N. Hirashima, M. Kikuchi, T. Nikami, Gideon M. Hirschfield, Carlo Ferrari, G. Prasad, O. Chirag, Katsushi Tokunaga, M. Nasseri, Rosanna Asselta, Y. Lu, Ken Shirabe, D. Sirdefield, George F. Mells, K. Sugi, R. Ayres, G. Whatley, A. Singhal, M. Leoni, N. Sivaramakrishnan, T. Harding, Rupert Ransford, Anton V J Gunasekera, C. Mulvaney-Jones, D. Ramanaden, M. Mendall, Muhammad F. Dawwas, Dave Jones, Luca Valenti, Earl J. Williams, Markus Gess, Peter Bramley, A. McNair, E. Hashimoto, P. Townshend, C. Ford, Mario Strazzabosco, Luca Miele, Matthew J Brookes, J. Colley, Mark Wilkinson, H. Dewhurst, Charles Millson, E. Shpuza, Shinji Shimoda, T. Himoto, P. Kitchen, M. Nakamuta, Hiroaki Nishimura, Martin Lombard, Kevork M. Peltekian, M. Pitcher, G. Lim, L. Graves, C. Palmer, S. Lord, S. Katsushima, S. Tripoli, Andrew Austin, N. White, B. Grover, S. Congreave, M. Prince, Rebecca Jones, K. Hirano, A. Shepherd, Y. Mano, Michael A. Heneghan, Richard Sandford, L. O'Donohoe, Marco Carbone, S. A. Rolls, Patrick Goggin, M. L. Cowan, M. Crossey, A. Loftus, K. Young, Mesbah Rahman, Cameron N. Ghent, E. Nambela, M. Xiong, L. Grellier, Sunil Dolwani, Antonio Picciotto, Gill Watts, Alberto Mattalia, Elvezia Maria Paraboschi, J. Orpe, Takeji Umemura, Yuki Hitomi, Fiona H. Gordon, Shotaro Sakisaka, A. Dias, Chin Lye Ch'ng, M. Carter, A. Mandal, Yufang Shi, Takafumi Ichida, N. Masaki, M. Oblak, S. Nagaoka, Kevin Yoong, O. Gervais, Minoru Nakamura, Kazuhiko Nakao, S. Taylor-Robinson, L. Kent, Sushma Saksena, A. Affronti, K. Boulton, R. Ede, H. Pateman, K. Yoshizawa, G. Bray, H. Ebinuma, Yeng Ang, Akio Ido, John Ramage, Richard Sturgess, C. Gray, E. Durant, M. Hayes, A. Saeed, J. Keggans, J. Gitahi, T. Valliani, Edoardo G. Giannini, C. Foale, A. Palegwala, Lory Saveria Crocè, K. Matsushita, S. Shaukat, J. Mclindon, S. Pearson, A. Barnardo, A. Wright, Mirko Tarocchi, R Marley, M. Kent, C. Dickson, A. Gibbins, J. Whiteman, S. Singhal, Richard Aspinall, M. Ito, Laura Cristoferi, Maurizia Rossana Brunetto, J. Booth, A. Bathgate, Morikazu Onji, A. Grant, A. Paton, Y. Aiba, P. Chan, J. Sayer, S. Whalley, T. Mathialahan, J. Gotto, T. Kanda, B. Williams, K. Elliott, P. Raymode, Akinobu Takaki, V. Silvestre, I. Gee, C. Hovell, Graham R. Foster, D. Cotterill, G. Stansfield, Grazia Anna Niro, J. Conder, Yoshiyuki Ueno, A. Shah, Jane Metcalf, S. Hayashi, T. Sato, S. Jain, J. Subhani, Donatella Barisani, A. McKay, Kuniaki Arai, Jeremy Shearman, Torao Tanaka, S. Glenn, S. E. O'Donnell, Federica Malinverno, Denise O'Donnell, R. Casey, N. Sharer, J. Bowles, J. Kendall, Maria Cristina Vinci, Antonio Benedetti, George MacFaul, K. Houghton, Vincenzo Ronca, P. Desousa, B. Holbrook, F. Ali, B. Longhurst, Atsushi Tanaka, Marek Czajkowski, R. Tang, Kazuhide Yamamoto, Y. Watanabe, Graeme J.M. Alexander, R. Cloudsdale, F. Hines, M. Karmo, Brian D. Juran, I. Gooding, Y. Takeyama, J. Fraser, A. Mukhopadhya, Sumihito Tamura, Hajime Takikawa, R. Damant, E. Wilhelmsen, M. Kobayashi, J. Tregonning, V. Lambourne, D. Clement, D. Braim, M. Shimada, S. Sen, Shaun Greer, C. Innes, E. Gunter, C. Brown, H. Klass, A. Komori, Andy Li, H. Fairlamb, N. Ncube, Yoshinori Shimada, M. Harrison, S. Marriott, I. Grattagliano, Savino Bruno, A. Naganuma, Xiangjun Gu, Michael F. Seldin, S. Thornthwaite, Peter R. Mills, Katherine A. Siminovitch, X. Liu, Masataka Seike, J. Curtis, Carmela Cursaro, Z. Li, Mikio Zeniya, K. Warner, B. Bird, Jane Collier, Bridget Gunson, S. Tsuruta, E. Tanqueray, Richard Evans, H. Kamitsukasa, R. Sugimoto, Jeremy Tibble, D. Neal, S. Ducker, Francesco Azzaroli, K. Spurdle, K. Ocker, M. Senju, C. Collins, Y. Nakamura, Matthew E. Cramp, Yuji Soejima, I. Drake, K. Ueno, T. Mannami, Clara Mancuso, M. Kawashima, M. Cox, S. S. Kohn, H. Shibata, Stephen D. Ryder, Christopher Macdonald, J. Ridpath, Stephen P. Pereira, L. March, Barbara Coco, J. Morrison, A. Broad, J. Verheyden, Angelo Andriulli, N. Higuchi, J. Musselwhite, R. Bishop, Gwen Baxter, Richard A. Miller, Guido Colloredo, A. Eastick, I. Rees, Deb Ghosh, L. Winter, Sara Massironi, R. McCorry, Gianfranco Elia, T. Kobata, N. Naeshiro, K. Pollock, J. Gasem, S. Gallagher, K. Jing, S. Misra, B. Shinder, Harriet Gordon, E. Takesaki, J. Sadeghian, S. Tsunematsu, Ana Lleo, M. Aldersley, Elizabeth J. Atkinson, Pietro Invernizzi, Heather J. Cordell, Asselta, R., Paraboschi, E. M., Gerussi, A., Cordell, H. J., Mells, G. F., Sandford, R. N., Jones, D. E., Nakamura, M., Ueno, K., Hitomi, Y., Kawashima, M., Nishida, N., Tokunaga, K., Nagasaki, M., Tanaka, A., Tang, R., Li, Z., Shi, Y., Liu, X., Xiong, M., Hirschfield, G., Siminovitch, K. A., Walker, E., Xie, G., Mason, A., Myers, R., Peltekian, K., Ghent, C., Atkinson, E., Juran, B., Lazaridis, K., Lu, Y., Gu, X., Jing, K., Amos, C., Affronti, A., Brunetto, M., Coco, B., Spinzi, G., Elia, G., Ferrari, C., Lleo, A., Muratori, L., Muratori, P., Portincasa, P., Colli, A., Bruno, S., Colloredo, G., Azzaroli, F., Andreone, P., Bragazzi, M., Alvaro, D., Cardinale, V., Cazzagon, N., Rigamonti, C., Floreani, A., Rosina, F., Ciaccio, A., Cristoferi, L., D'Amato, D., Malinverno, F., Mancuso, C., Massironi, S., Milani, C., O'Donnell, S. E., Ronca, V., Barisani, D., Lampertico, P., Donato, F., Fagiuoli, S., Almasio, P. L., Giannini, E., Cursaro, C., Colombo, M., Valenti, L., Miele, L., Andriulli, A., Niro, G. A., Grattagliano, I., Morini, L., Casella, G., Vinci, M., Battezzati, P. M., Crosignani, A., Zuin, M., Mattalia, A., Calvaruso, V., Colombo, S., Benedetti, A., Marzioni, M., Galli, A., Marra, F., Tarocchi, M., Picciotto, A., Morisco, F., Fabris, L., Croce, L. S., Tiribelli, C., Toniutto, P., Strazzabosco, M., Ch'Ng, C. L., Rahman, M., Yapp, T., Sturgess, R., Healey, C., Czajkowski, M., Gunasekera, A., Gyawali, P., Premchand, P., Kapur, K., Marley, R., Foster, G., Watson, A., Dias, A., Subhani, J., Harvey, R., Mccorry, R., Ramanaden, D., Gasem, J., Evans, R., Mathialahan, T., Shorrock, C., Lipscomb, G., Southern, P., Tibble, J., Gorard, D., Palegwala, A., Jones, S., Dawwas, M., Alexander, G., Dolwani, S., Prince, M., Foxton, M., Elphick, D., Mitchison, H., Gooding, I., Karmo, M., Saksena, S., Mendall, M., Patel, M., Ede, R., Austin, A., Sayer, J., Hankey, L., Hovell, C., Fisher, N., Carter, M., Koss, K., Piotrowicz, A., Grimley, C., Neal, D., Lim, G., Levi, S., Ala, A., Broad, A., Saeed, A., Wood, G., Brown, J., Wilkinson, M., Gordon, H., Ramage, J., Ridpath, J., Ngatchu, T., Grover, B., Shaukat, S., Shidrawi, R., Abouda, G., Ali, F., Rees, I., Salam, I., Narain, M., Brown, A., Taylor-Robinson, S., Williams, S., Grellier, L., Banim, P., Das, D., Chilton, A., Heneghan, M., Curtis, H., Gess, M., Drake, I., Aldersley, M., Davies, M., Jones, R., Mcnair, A., Srirajaskanthan, R., Pitcher, M., Sen, S., Bird, G., Barnardo, A., Kitchen, P., Yoong, K., Chirag, O., Sivaramakrishnan, N., Macfaul, G., Jones, D., Shah, A., Evans, C., Saha, S., Pollock, K., Bramley, P., Mukhopadhya, A., Fraser, A., Mills, P., Shallcross, C., Campbell, S., Bathgate, A., Shepherd, A., Dillon, J., Rushbrook, S., Przemioslo, R., Macdonald, C., Metcalf, J., Shmueli, U., Davis, A., Naqvi, A., Lee, T., Ryder, S. D., Collier, J., Klass, H., Ninkovic, M., Cramp, M., Sharer, N., Aspinall, R., Goggin, P., Ghosh, D., Douds, A., Hoeroldt, B., Booth, J., Williams, E., Hussaini, H., Stableforth, W., Ayres, R., Thorburn, D., Marshall, E., Burroughs, A., Mann, S., Lombard, M., Richardson, P., Patanwala, I., Maltby, J., Brookes, M., Mathew, R., Vyas, S., Singhal, S., Gleeson, D., Misra, S., Butterworth, J., George, K., Harding, T., Douglass, A., Panter, S., Shearman, J., Bray, G., Butcher, G., Forton, D., Mclindon, J., Cowan, M., Whatley, G., Mandal, A., Gupta, H., Sanghi, P., Jain, S., Pereira, S., Prasad, G., Watts, G., Wright, M., Neuberger, J., Gordon, F., Unitt, E., Grant, A., Delahooke, T., Higham, A., Brind, A., Cox, M., Ramakrishnan, S., King, A., Collins, C., Whalley, S., Li, A., Fraser, J., Bell, A., Wong, V. S., Singhal, A., Gee, I., Ang, Y., Ransford, R., Gotto, J., Millson, C., Bowles, J., Thomas, C., Harrison, M., Galaska, R., Kendall, J., Whiteman, J., Lawlor, C., Gray, C., Elliott, K., Mulvaney-Jones, C., Hobson, L., Van Duyvenvoorde, G., Loftus, A., Seward, K., Penn, R., Maiden, J., Damant, R., Hails, J., Cloudsdale, R., Silvestre, V., Glenn, S., Dungca, E., Wheatley, N., Doyle, H., Kent, M., Hamilton, C., Braim, D., Wooldridge, H., Abrahams, R., Paton, A., Lancaster, N., Gibbins, A., Hogben, K., Desousa, P., Muscariu, F., Musselwhite, J., Mckay, A., Tan, L., Foale, C., Brighton, J., Flahive, K., Nambela, E., Townshend, P., Ford, C., Holder, S., Palmer, C., Featherstone, J., Nasseri, M., Sadeghian, J., Williams, B., Rolls, S. -A., Hynes, A., Duggan, C., Crossey, M., Stansfield, G., Macnicol, C., Wilkins, J., Wilhelmsen, E., Raymode, P., Lee, H. -J., Durant, E., Bishop, R., Ncube, N., Tripoli, S., Casey, R., Cowley, C., Miller, R., Houghton, K., Ducker, S., Wright, F., Bird, B., Baxter, G., Keggans, J., Hughes, M., Grieve, E., Young, K., Williams, D., Ocker, K., Hines, F., Martin, K., Innes, C., Valliani, T., Fairlamb, H., Thornthwaite, S., Eastick, A., Tanqueray, E., Morrison, J., Holbrook, B., Browning, J., Walker, K., Congreave, S., Verheyden, J., Slininger, S., Stafford, L., O'Donnell, D., Ainsworth, M., Lord, S., Kent, L., March, L., Dickson, C., Simpson, D., Longhurst, B., Hayes, M., Shpuza, E., White, N., Besley, S., Pearson, S., Wright, A., Jones, L., Gunter, E., Dewhurst, H., Fouracres, A., Farrington, L., Graves, L., Marriott, S., Leoni, M., Tyrer, D., Dali-kemmery, L., Lambourne, V., Green, M., Sirdefield, D., Amor, K., Colley, J., Shinder, B., Jones, J., Mills, M., Carnahan, M., Taylor, N., Boulton, K., Tregonning, J., Brown, C., Clifford, G., Archer, E., Hamilton, M., Curtis, J., Shewan, T., Walsh, S., Warner, K., Netherton, K., Mupudzi, M., Gunson, B., Gitahi, J., Gocher, D., Batham, S., Pateman, H., Desmennu, S., Conder, J., Clement, D., Gallagher, S., Orpe, J., Chan, P., Currie, L., O'Donohoe, L., Oblak, M., Morgan, L., Quinn, M., Amey, I., Baird, Y., Cotterill, D., Cumlat, L., Winter, L., Greer, S., Spurdle, K., Allison, J., Dyer, S., Sweeting, H., Kordula, J., Aiba, Y., Nakamura, H., Abiru, S., Nagaoka, S., Komori, A., Yatsuhashi, H., Ishibashi, H., Ito, M., Kawai, Y., Kohn, S. -S., Gervais, O., Migita, K., Katsushima, S., Naganuma, A., Sugi, K., Komatsu, T., Mannami, T., Matsushita, K., Yoshizawa, K., Makita, F., Nikami, T., Nishimura, H., Kouno, H., Ota, H., Komura, T., Nakamura, Y., Shimada, M., Hirashima, N., Komeda, T., Ario, K., Nakamuta, M., Yamashita, T., Furuta, K., Kikuchi, M., Naeshiro, N., Takahashi, H., Mano, Y., Tsunematsu, S., Yabuuchi, I., Shimada, Y., Yamauchi, K., Sugimoto, R., Sakai, H., Mita, E., Koda, M., Tsuruta, S., Kamitsukasa, H., Sato, T., Masaki, N., Kobata, T., Fukushima, N., Higuchi, N., Ohara, Y., Muro, T., Takesaki, E., Takaki, H., Yamamoto, T., Kato, M., Nagaoki, Y., Hayashi, S., Ishida, J., Watanabe, Y., Kobayashi, M., Koga, M., Saoshiro, T., Yagura, M., Hirata, K., Takikawa, H., Ohira, H., Zeniya, M., Abe, M., Onji, M., Kaneko, S., Honda, M., Arai, K., Arinaga-Hino, T., Hashimoto, E., Taniai, M., Umemura, T., Joshita, S., Nakao, K., Ichikawa, T., Shibata, H., Yamagiwa, S., Seike, M., Honda, K., Sakisaka, S., Takeyama, Y., Harada, M., Senju, M., Yokosuka, O., Kanda, T., Ueno, Y., Kikuchi, K., Ebinuma, H., Himoto, T., Yasunami, M., Murata, K., Mizokami, M., Shimoda, S., Miyake, Y., Takaki, A., Yamamoto, K., Hirano, K., Ichida, T., Ido, A., Tsubouchi, H., Chayama, K., Harada, K., Nakanuma, Y., Maehara, Y., Taketomi, A., Shirabe, K., Soejima, Y., Mori, A., Yagi, S., Uemoto, S., Tanaka, T., Yamashiki, N., Tamura, S., Sugawara, Y., Kokudo, N., Carbone, M., Cardamone, G., Duga, S., Gershwin, M. E., Seldin, M. F., Invernizzi, P., Asselta R., Paraboschi E.M., Gerussi A., Cordell H.J., Mells G.F., Sandford R.N., Jones D.E., Nakamura M., Ueno K., Hitomi Y., Kawashima M., Nishida N., Tokunaga K., Nagasaki M., Tanaka A., Tang R., Li Z., Shi Y., Liu X., Xiong M., Hirschfield G., Siminovitch K.A., Walker E., Xie G., Mason A., Myers R., Peltekian K., Ghent C., Atkinson E., Juran B., Lazaridis K., Lu Y., Gu X., Jing K., Amos C., Affronti A., Brunetto M., Coco B., Spinzi G., Elia G., Ferrari C., Lleo A., Muratori L., Muratori P., Portincasa P., Colli A., Bruno S., Colloredo G., Azzaroli F., Andreone P., Bragazzi M., Alvaro D., Cardinale V., Cazzagon N., Rigamonti C., Floreani A., Rosina F., Ciaccio A., Cristoferi L., D'Amato D., Malinverno F., Mancuso C., Massironi S., Milani C., O'Donnell S.E., Ronca V., Barisani D., Lampertico P., Donato F., Fagiuoli S., Almasio P.L., Giannini E., Cursaro C., Colombo M., Valenti L., Miele L., Andriulli A., Niro G.A., Grattagliano I., Morini L., Casella G., Vinci M., Battezzati P.M., Crosignani A., Zuin M., Mattalia A., Calvaruso V., Colombo S., Benedetti A., Marzioni M., Galli A., Marra F., Tarocchi M., Picciotto A., Morisco F., Fabris L., Croce L.S., Tiribelli C., Toniutto P., Strazzabosco M., Ch'ng C.L., Rahman M., Yapp T., Sturgess R., Healey C., Czajkowski M., Gunasekera A., Gyawali P., Premchand P., Kapur K., Marley R., Foster G., Watson A., Dias A., Subhani J., Harvey R., McCorry R., Ramanaden D., Gasem J., Evans R., Mathialahan T., Shorrock C., Lipscomb G., Southern P., Tibble J., Gorard D., Palegwala A., Jones S., Dawwas M., Alexander G., Dolwani S., Prince M., Foxton M., Elphick D., Mitchison H., Gooding I., Karmo M., Saksena S., Mendall M., Patel M., Ede R., Austin A., Sayer J., Hankey L., Hovell C., Fisher N., Carter M., Koss K., Piotrowicz A., Grimley C., Neal D., Lim G., Levi S., Ala A., Broad A., Saeed A., Wood G., Brown J., Wilkinson M., Gordon H., Ramage J., Ridpath J., Ngatchu T., Grover B., Shaukat S., Shidrawi R., Abouda G., Ali F., Rees I., Salam I., Narain M., Brown A., Taylor-Robinson S., Williams S., Grellier L., Banim P., Das D., Chilton A., Heneghan M., Curtis H., Gess M., Drake I., Aldersley M., Davies M., Jones R., McNair A., Srirajaskanthan R., Pitcher M., Sen S., Bird G., Barnardo A., Kitchen P., Yoong K., Chirag O., Sivaramakrishnan N., MacFaul G., Jones D., Shah A., Evans C., Saha S., Pollock K., Bramley P., Mukhopadhya A., Fraser A., Mills P., Shallcross C., Campbell S., Bathgate A., Shepherd A., Dillon J., Rushbrook S., Przemioslo R., Macdonald C., Metcalf J., Shmueli U., Davis A., Naqvi A., Lee T., Ryder S.D., Collier J., Klass H., Ninkovic M., Cramp M., Sharer N., Aspinall R., Goggin P., Ghosh D., Douds A., Hoeroldt B., Booth J., Williams E., Hussaini H., Stableforth W., Ayres R., Thorburn D., Marshall E., Burroughs A., Mann S., Lombard M., Richardson P., Patanwala I., Maltby J., Brookes M., Mathew R., Vyas S., Singhal S., Gleeson D., Misra S., Butterworth J., George K., Harding T., Douglass A., Panter S., Shearman J., Bray G., Butcher G., Forton D., Mclindon J., Cowan M., Whatley G., Mandal A., Gupta H., Sanghi P., Jain S., Pereira S., Prasad G., Watts G., Wright M., Neuberger J., Gordon F., Unitt E., Grant A., Delahooke T., Higham A., Brind A., Cox M., Ramakrishnan S., King A., Collins C., Whalley S., Li A., Fraser J., Bell A., Wong V.S., Singhal A., Gee I., Ang Y., Ransford R., Gotto J., Millson C., Bowles J., Thomas C., Harrison M., Galaska R., Kendall J., Whiteman J., Lawlor C., Gray C., Elliott K., Mulvaney-Jones C., Hobson L., Van Duyvenvoorde G., Loftus A., Seward K., Penn R., Maiden J., Damant R., Hails J., Cloudsdale R., Silvestre V., Glenn S., Dungca E., Wheatley N., Doyle H., Kent M., Hamilton C., Braim D., Wooldridge H., Abrahams R., Paton A., Lancaster N., Gibbins A., Hogben K., Desousa P., Muscariu F., Musselwhite J., McKay A., Tan L., Foale C., Brighton J., Flahive K., Nambela E., Townshend P., Ford C., Holder S., Palmer C., Featherstone J., Nasseri M., Sadeghian J., Williams B., Rolls S.-A., Hynes A., Duggan C., Crossey M., Stansfield G., MacNicol C., Wilkins J., Wilhelmsen E., Raymode P., Lee H.-J., Durant E., Bishop R., Ncube N., Tripoli S., Casey R., Cowley C., Miller R., Houghton K., Ducker S., Wright F., Bird B., Baxter G., Keggans J., Hughes M., Grieve E., Young K., Williams D., Ocker K., Hines F., Martin K., Innes C., Valliani T., Fairlamb H., Thornthwaite S., Eastick A., Tanqueray E., Morrison J., Holbrook B., Browning J., Walker K., Congreave S., Verheyden J., Slininger S., Stafford L., O'Donnell D., Ainsworth M., Lord S., Kent L., March L., Dickson C., Simpson D., Longhurst B., Hayes M., Shpuza E., White N., Besley S., Pearson S., Wright A., Jones L., Gunter E., Dewhurst H., Fouracres A., Farrington L., Graves L., Marriott S., Leoni M., Tyrer D., Dali-kemmery L., Lambourne V., Green M., Sirdefield D., Amor K., Colley J., Shinder B., Jones J., Mills M., Carnahan M., Taylor N., Boulton K., Tregonning J., Brown C., Clifford G., Archer E., Hamilton M., Curtis J., Shewan T., Walsh S., Warner K., Netherton K., Mupudzi M., Gunson B., Gitahi J., Gocher D., Batham S., Pateman H., Desmennu S., Conder J., Clement D., Gallagher S., Orpe J., Chan P., Currie L., O'Donohoe L., Oblak M., Morgan L., Quinn M., Amey I., Baird Y., Cotterill D., Cumlat L., Winter L., Greer S., Spurdle K., Allison J., Dyer S., Sweeting H., Kordula J., Aiba Y., Nakamura H., Abiru S., Nagaoka S., Komori A., Yatsuhashi H., Ishibashi H., Ito M., Kawai Y., Kohn S.-S., Gervais O., Migita K., Katsushima S., Naganuma A., Sugi K., Komatsu T., Mannami T., Matsushita K., Yoshizawa K., Makita F., Nikami T., Nishimura H., Kouno H., Ota H., Komura T., Nakamura Y., Shimada M., Hirashima N., Komeda T., Ario K., Nakamuta M., Yamashita T., Furuta K., Kikuchi M., Naeshiro N., Takahashi H., Mano Y., Tsunematsu S., Yabuuchi I., Shimada Y., Yamauchi K., Sugimoto R., Sakai H., Mita E., Koda M., Tsuruta S., Kamitsukasa H., Sato T., Masaki N., Kobata T., Fukushima N., Higuchi N., Ohara Y., Muro T., Takesaki E., Takaki H., Yamamoto T., Kato M., Nagaoki Y., Hayashi S., Ishida J., Watanabe Y., Kobayashi M., Koga M., Saoshiro T., Yagura M., Hirata K., Takikawa H., Ohira H., Zeniya M., Abe M., Onji M., Kaneko S., Honda M., Arai K., Arinaga-Hino T., Hashimoto E., Taniai M., Umemura T., Joshita S., Nakao K., Ichikawa T., Shibata H., Yamagiwa S., Seike M., Honda K., Sakisaka S., Takeyama Y., Harada M., Senju M., Yokosuka O., Kanda T., Ueno Y., Kikuchi K., Ebinuma H., Himoto T., Yasunami M., Murata K., Mizokami M., Shimoda S., Miyake Y., Takaki A., Yamamoto K., Hirano K., Ichida T., Ido A., Tsubouchi H., Chayama K., Harada K., Nakanuma Y., Maehara Y., Taketomi A., Shirabe K., Soejima Y., Mori A., Yagi S., Uemoto S., Tanaka T., Yamashiki N., Tamura S., Sugawara Y., Kokudo N., Carbone M., Cardamone G., Duga S., Gershwin M.E., Seldin M.F., Invernizzi P., Asselta, R, Paraboschi, E, Gerussi, A, Cordell, H, Mells, G, Sandford, R, Jones, D, Nakamura, M, Ueno, K, Hitomi, Y, Kawashima, M, Nishida, N, Tokunaga, K, Nagasaki, M, Tanaka, A, Tang, R, Li, Z, Shi, Y, Liu, X, Xiong, M, Hirschfield, G, Siminovitch, K, Walker, E, Xie, G, Mason, A, Myers, R, Peltekian, K, Ghent, C, Atkinson, E, Juran, B, Lazaridis, K, Lu, Y, Gu, X, Jing, K, Amos, C, Affronti, A, Brunetto, M, Coco, B, Spinzi, G, Elia, G, Ferrari, C, Lleo, A, Muratori, L, Muratori, P, Portincasa, P, Colli, A, Bruno, S, Colloredo, G, Azzaroli, F, Andreone, P, Bragazzi, M, Alvaro, D, Cardinale, V, Cazzagon, N, Rigamonti, C, Floreani, A, Rosina, F, Ciaccio, A, Cristoferi, L, D'Amato, D, Malinverno, F, Mancuso, C, Massironi, S, Milani, C, O'Donnell, S, Ronca, V, Barisani, D, Lampertico, P, Donato, F, Fagiuoli, S, Almasio, P, Giannini, E, Cursaro, C, Colombo, M, Valenti, L, Miele, L, Andriulli, A, Niro, G, Grattagliano, I, Morini, L, Casella, G, Vinci, M, Battezzati, P, Crosignani, A, Zuin, M, Mattalia, A, Calvaruso, V, Colombo, S, Benedetti, A, Marzioni, M, Galli, A, Marra, F, Tarocchi, M, Picciotto, A, Morisco, F, Fabris, L, Croce, L, Tiribelli, C, Toniutto, P, Strazzabosco, M, Ch'Ng, C, Rahman, M, Yapp, T, Sturgess, R, Healey, C, Czajkowski, M, Gunasekera, A, Gyawali, P, Premchand, P, Kapur, K, Marley, R, Foster, G, Watson, A, Dias, A, Subhani, J, Harvey, R, Mccorry, R, Ramanaden, D, Gasem, J, Evans, R, Mathialahan, T, Shorrock, C, Lipscomb, G, Southern, P, Tibble, J, Gorard, D, Palegwala, A, Jones, S, Dawwas, M, Alexander, G, Dolwani, S, Prince, M, Foxton, M, Elphick, D, Mitchison, H, Gooding, I, Karmo, M, Saksena, S, Mendall, M, Patel, M, Ede, R, Austin, A, Sayer, J, Hankey, L, Hovell, C, Fisher, N, Carter, M, Koss, K, Piotrowicz, A, Grimley, C, Neal, D, Lim, G, Levi, S, Ala, A, Broad, A, Saeed, A, Wood, G, Brown, J, Wilkinson, M, Gordon, H, Ramage, J, Ridpath, J, Ngatchu, T, Grover, B, Shaukat, S, Shidrawi, R, Abouda, G, Ali, F, Rees, I, Salam, I, Narain, M, Brown, A, Taylor-Robinson, S, Williams, S, Grellier, L, Banim, P, Das, D, Chilton, A, Heneghan, M, Curtis, H, Gess, M, Drake, I, Aldersley, M, Davies, M, Jones, R, Mcnair, A, Srirajaskanthan, R, Pitcher, M, Sen, S, Bird, G, Barnardo, A, Kitchen, P, Yoong, K, Chirag, O, Sivaramakrishnan, N, Macfaul, G, Shah, A, Evans, C, Saha, S, Pollock, K, Bramley, P, Mukhopadhya, A, Fraser, A, Mills, P, Shallcross, C, Campbell, S, Bathgate, A, Shepherd, A, Dillon, J, Rushbrook, S, Przemioslo, R, Macdonald, C, Metcalf, J, Shmueli, U, Davis, A, Naqvi, A, Lee, T, Ryder, S, Collier, J, Klass, H, Ninkovic, M, Cramp, M, Sharer, N, Aspinall, R, Goggin, P, Ghosh, D, Douds, A, Hoeroldt, B, Booth, J, Williams, E, Hussaini, H, Stableforth, W, Ayres, R, Thorburn, D, Marshall, E, Burroughs, A, Mann, S, Lombard, M, Richardson, P, Patanwala, I, Maltby, J, Brookes, M, Mathew, R, Vyas, S, Singhal, S, Gleeson, D, Misra, S, Butterworth, J, George, K, Harding, T, Douglass, A, Panter, S, Shearman, J, Bray, G, Butcher, G, Forton, D, Mclindon, J, Cowan, M, Whatley, G, Mandal, A, Gupta, H, Sanghi, P, Jain, S, Pereira, S, Prasad, G, Watts, G, Wright, M, Neuberger, J, Gordon, F, Unitt, E, Grant, A, Delahooke, T, Higham, A, Brind, A, Cox, M, Ramakrishnan, S, King, A, Collins, C, Whalley, S, Li, A, Fraser, J, Bell, A, Wong, V, Singhal, A, Gee, I, Ang, Y, Ransford, R, Gotto, J, Millson, C, Bowles, J, Thomas, C, Harrison, M, Galaska, R, Kendall, J, Whiteman, J, Lawlor, C, Gray, C, Elliott, K, Mulvaney-Jones, C, Hobson, L, Van Duyvenvoorde, G, Loftus, A, Seward, K, Penn, R, Maiden, J, Damant, R, Hails, J, Cloudsdale, R, Silvestre, V, Glenn, S, Dungca, E, Wheatley, N, Doyle, H, Kent, M, Hamilton, C, Braim, D, Wooldridge, H, Abrahams, R, Paton, A, Lancaster, N, Gibbins, A, Hogben, K, Desousa, P, Muscariu, F, Musselwhite, J, Mckay, A, Tan, L, Foale, C, Brighton, J, Flahive, K, Nambela, E, Townshend, P, Ford, C, Holder, S, Palmer, C, Featherstone, J, Nasseri, M, Sadeghian, J, Williams, B, Rolls, S, Hynes, A, Duggan, C, Crossey, M, Stansfield, G, Macnicol, C, Wilkins, J, Wilhelmsen, E, Raymode, P, Lee, H, Durant, E, Bishop, R, Ncube, N, Tripoli, S, Casey, R, Cowley, C, Miller, R, Houghton, K, Ducker, S, Wright, F, Bird, B, Baxter, G, Keggans, J, Hughes, M, Grieve, E, Young, K, Williams, D, Ocker, K, Hines, F, Martin, K, Innes, C, Valliani, T, Fairlamb, H, Thornthwaite, S, Eastick, A, Tanqueray, E, Morrison, J, Holbrook, B, Browning, J, Walker, K, Congreave, S, Verheyden, J, Slininger, S, Stafford, L, O'Donnell, D, Ainsworth, M, Lord, S, Kent, L, March, L, Dickson, C, Simpson, D, Longhurst, B, Hayes, M, Shpuza, E, White, N, Besley, S, Pearson, S, Wright, A, Jones, L, Gunter, E, Dewhurst, H, Fouracres, A, Farrington, L, Graves, L, Marriott, S, Leoni, M, Tyrer, D, Dali-kemmery, L, Lambourne, V, Green, M, Sirdefield, D, Amor, K, Colley, J, Shinder, B, Jones, J, Mills, M, Carnahan, M, Taylor, N, Boulton, K, Tregonning, J, Brown, C, Clifford, G, Archer, E, Hamilton, M, Curtis, J, Shewan, T, Walsh, S, Warner, K, Netherton, K, Mupudzi, M, Gunson, B, Gitahi, J, Gocher, D, Batham, S, Pateman, H, Desmennu, S, Conder, J, Clement, D, Gallagher, S, Orpe, J, Chan, P, Currie, L, O'Donohoe, L, Oblak, M, Morgan, L, Quinn, M, Amey, I, Baird, Y, Cotterill, D, Cumlat, L, Winter, L, Greer, S, Spurdle, K, Allison, J, Dyer, S, Sweeting, H, Kordula, J, Aiba, Y, Nakamura, H, Abiru, S, Nagaoka, S, Komori, A, Yatsuhashi, H, Ishibashi, H, Ito, M, Kawai, Y, Kohn, S, Gervais, O, Migita, K, Katsushima, S, Naganuma, A, Sugi, K, Komatsu, T, Mannami, T, Matsushita, K, Yoshizawa, K, Makita, F, Nikami, T, Nishimura, H, Kouno, H, Ota, H, Komura, T, Nakamura, Y, Shimada, M, Hirashima, N, Komeda, T, Ario, K, Nakamuta, M, Yamashita, T, Furuta, K, Kikuchi, M, Naeshiro, N, Takahashi, H, Mano, Y, Tsunematsu, S, Yabuuchi, I, Shimada, Y, Yamauchi, K, Sugimoto, R, Sakai, H, Mita, E, Koda, M, Tsuruta, S, Kamitsukasa, H, Sato, T, Masaki, N, Kobata, T, Fukushima, N, Higuchi, N, Ohara, Y, Muro, T, Takesaki, E, Takaki, H, Yamamoto, T, Kato, M, Nagaoki, Y, Hayashi, S, Ishida, J, Watanabe, Y, Kobayashi, M, Koga, M, Saoshiro, T, Yagura, M, Hirata, K, Takikawa, H, Ohira, H, Zeniya, M, Abe, M, Onji, M, Kaneko, S, Honda, M, Arai, K, Arinaga-Hino, T, Hashimoto, E, Taniai, M, Umemura, T, Joshita, S, Nakao, K, Ichikawa, T, Shibata, H, Yamagiwa, S, Seike, M, Honda, K, Sakisaka, S, Takeyama, Y, Harada, M, Senju, M, Yokosuka, O, Kanda, T, Ueno, Y, Kikuchi, K, Ebinuma, H, Himoto, T, Yasunami, M, Murata, K, Mizokami, M, Shimoda, S, Miyake, Y, Takaki, A, Yamamoto, K, Hirano, K, Ichida, T, Ido, A, Tsubouchi, H, Chayama, K, Harada, K, Nakanuma, Y, Maehara, Y, Taketomi, A, Shirabe, K, Soejima, Y, Mori, A, Yagi, S, Uemoto, S, Tanaka, T, Yamashiki, N, Tamura, S, Sugawara, Y, Kokudo, N, Carbone, M, Cardamone, G, Duga, S, Gershwin, M, Seldin, M, Invernizzi, P, Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, Jones DE, Nakamura M, Ueno K, Hitomi Y, Kawashima M, Nishida N, Tokunaga K, Nagasaki M, Tanaka A, Tang R, Li Z, Shi Y, Liu X, Xiong M, Hirschfield G, Siminovitch KA, Canadian-US PBC Consortium, Italian PBC Genetics Study Group, UK-PBC Consortium, Japan PBC-GWAS Consortium, Carbone M, Cardamone G, Duga S, Gershwin ME, Seldin MF, Invernizzi P, and LiveR North
Subjects: Canadian-US PBC Consortium, 0301 basic medicine, Male, Linkage disequilibrium, Genome-wide association study, Disease, PBC, Settore MED/03 - GENETICA MEDICA, Linkage Disequilibrium, 0302 clinical medicine, UK-PBC Consortium, Genotype, Mitochondrial Precursor Protein Import Complex Proteins, Italian PBC Genetics Study Group, Odds Ratio, X-Wide Association Study, Japan PBC-GWAS Consortium, X chromosome, Genetics, Liver Cirrhosis, Biliary, Gastroenterology, Forkhead Transcription Factors, DNA-Binding Proteins, Shal Potassium Channels, 030211 gastroenterology & hepatology, Female, Adult, Monosaccharide Transport Proteins, Superenhancer, Locus (genetics), Single-nucleotide polymorphism, Biology, Protein Serine-Threonine Kinases, Polymorphism, Single Nucleotide, Article, White People, 03 medical and health sciences, Asian People, Proto-Oncogene Proteins, Endopeptidases, Humans, Cell Lineage, Genetic Predisposition to Disease, Meta-analysi, Genetic association, Chromosomes, Human, X, Gastroenterology & Hepatology, Hepatology, 1103 Clinical Sciences, Meta-analysis, 030104 developmental biology, Genetic Loci, 1114 Paediatrics and Reproductive Medicine, 1109 Neurosciences, Carrier Proteins, Genome-Wide Association Study
Abstract: Background & aims: Genome-wide association studies in primary biliary cholangitis (PBC) have failed to find X chromosome (chrX) variants associated with the disease. Here, we specifically explore the chrX contribution to PBC, a sexually dimorphic complex autoimmune disease. Methods: We performed a chrX-wide association study, including genotype data from 5 genome-wide association studies (from Italy, United Kingdom, Canada, China, and Japan; 5244 case patients and 11,875 control individuals). Results: Single-marker association analyses found approximately 100 loci displaying P < 5 × 10-4, with the most significant being a signal within the OTUD5 gene (rs3027490; P = 4.80 × 10-6; odds ratio [OR], 1.39; 95% confidence interval [CI], 1.028-1.88; Japanese cohort). Although the transethnic meta-analysis evidenced only a suggestive signal (rs2239452, mapping within the PIM2 gene; OR, 1.17; 95% CI, 1.09-1.26; P = 9.93 × 10-8), the population-specific meta-analysis showed a genome-wide significant locus in East Asian individuals pointing to the same region (rs7059064, mapping within the GRIPAP1 gene; P = 6.2 × 10-9; OR, 1.33; 95% CI, 1.21-1.46). Indeed, rs7059064 tags a unique linkage disequilibrium block including 7 genes: TIMM17B, PQBP1, PIM2, SLC35A2, OTUD5, KCND1, and GRIPAP1, as well as a superenhancer (GH0XJ048933 within OTUD5) targeting all these genes. GH0XJ048933 is also predicted to target FOXP3, the main T-regulatory cell lineage specification factor. Consistently, OTUD5 and FOXP3 RNA levels were up-regulated in PBC case patients (1.75- and 1.64-fold, respectively). Conclusions: This work represents the first comprehensive study, to our knowledge, of the chrX contribution to the genetics of an autoimmune liver disease and shows a novel PBC-related genome-wide significant locus.
Published: 2021

5. Accuracy and inter-observer agreement of the nice and kudo classifications of superficial colonic lesions: a comparative study

Author: Francesco Perri, Sonia Carparelli, Antonella Marra, Alfredo Di Leo, Massimiliano Copetti, Rossella Cubisino, Francesco Cocomazzi, Fabrizio Bossa, M. Gentile, Paola Parente, Angelo Andriulli, Mariano Piazzolla, Antonio Massimo Ippolito, Paolo Graziano, Antonio Merla, Rosa Paolillo, and Alessia Mileti
Subjects: medicine.medical_specialty, business.industry, Inter observer agreement, Gastroenterology, Magnification, Nice, Diagnostic accuracy, Gold standard (test), 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Medicine, 030211 gastroenterology & hepatology, Radiology, Differential diagnosis, business, computer, health care economics and organizations, computer.programming_language
Abstract: For superficial colonic lesions, the NICE and Kudo classifications are used in the in vivo prediction of histology and as guide to therapy. The NICE system derives information from unmagnified NBI endoscopic images. The Kudo one necessitates a magnification, but, as this tool is not commonly available, it is applied also to characterize unmagnified pictures to compare their diagnostic performances. We conducted a prospective comparison of the NICE versus the Kudo classification for the differential diagnosis of colonic polyps taking histology as the gold standard. The inter-observer agreement for both classifications among 11 colonoscopists was also evaluated. Short unmagnified NBI videoclips of 64 colonic polyps were sent twice to the participants. In the first round, they classified the lesions according to the NICE classification; 4 months later, the same videos were assessed with the Kudo system. The diagnosis provided by the participants was grouped in non-neoplastic, non-invasive neoplasia, invasive neoplasia. Overall, the diagnostic accuracy was 82% (95%CI: 79–85) with the NICE system and 81% (95%CI: 78–84) with the Kudo one (ρ = 0.78). The accuracy of the NICE classification for non-neoplastic lesions was greater compared with the Kudo’s (ρ = 0.03). Sensitivity sub-analyses revealed a higher ability of the NICE in distinguishing between neoplastic vs. non-neoplastic lesions (ρ = 0.01). The overall inter-rater agreement did not differ when the classifications were compared. The NICE and the Kudo classifications might be considered comparable. Our data could allow the use of the NBI Kudo classification even in those centers where magnification is not available.
Published: 2021

6. Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis

Author: A. Amoruso, Nicola Caporaso, Grazia Anna Niro, N. Andriulli, Michele Pier Luca Guarino, Monica Greco, M. Librandi, Antonio Massimo Ippolito, Maria Rosa Valvano, Filomena Morisco, Angelo Andriulli, A. Iacobellis, Guarino, Maria, Morisco, Filomena, Valvano, M. R, Ippolito, A. M, Librandi, M, Andriulli, N, Greco, M, Amoruso, A, Iacobellis, A, Niro, G, Caporaso, Nicola, and Andriulli, A.
Subjects: Liver Cirrhosis, Ledipasvir, Simeprevir, medicine.medical_specialty, Cirrhosis, Daclatasvir, Sofosbuvir, Hepatitis C virus, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, Internal medicine, medicine, Humans, Protease Inhibitors, Pharmacology (medical), Hepatology, business.industry, Ribavirin, Gastroenterology, medicine.disease, Hepatitis C, Surgery, chemistry, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Interferons, business, medicine.drug
Abstract: SummaryBackground It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis. Aim To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection. Methods A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate. Results Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9% (95% CI: 65.6–82.4%). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4% (95% CI: 46.8–80.2) after sofosbuvir/simeprevir, 76.0% (95% CI: 54.4–89.3%) after sofosbuvir/daclatasvir and 83.0% (95% CI: 73.4–89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1% of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1% of patients. Conclusion The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.
Published: 2017

7. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease

Author: Fabrizio Bossa, Giuseppe Biscaglia, R. Lovero, Mariabeatrice Principi, Rosa Federica La Fortezza, M. Nardella, Giuseppe Losurdo, Giuseppina Martino, Fulvia Terracciano, Alfredo Di Leo, and Angelo Andriulli
Subjects: Male, medicine.medical_specialty, Inflammatory bowel disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Gastrointestinal Agents, Internal medicine, medicine, Humans, Adverse effect, Biosimilar Pharmaceuticals, Retrospective Studies, Univariate analysis, Hepatology, biology, business.industry, C-reactive protein, Antibodies, Monoclonal, Odds ratio, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Infliximab, Confidence interval, Treatment Outcome, 030220 oncology & carcinogenesis, biology.protein, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract: Introduction For patients with inflammatory bowel diseases, switching from infliximab originator to biosimilars is effective and safe. Few data on single switch have been published, and data on multiple switches of different infliximab are unavailable. Methods A retrospective analysis of patients who switched from CT-P13 to SB2, and of those with multiple switches among different infliximab compounds was conducted. Clinical activity, C reactive protein (CRP), adverse events (AE) and loss of response (LOR) were recorded. Results Thirty-six patients (26 males, 14 Crohn's disease and 22 ulcerative colitis) were enrolled and followed up for >6 months. All patients switched from CT-P13 to SB2; 12 of them (33.3%) had already switched from reference Infliximab to CT-P13, and for the remaining patients CT-P13 was the first infliximab. The clinical remission rate six months before and three months after SB2-switch was the same (58.3%) and the rate of mild activity varied from 27.8 to 33.3% (P = 0.68); the percentage of patients with normal CRP values passed from 94.4 to 91.7% (P = 1). Two patients (5.5%) had AE and 11 (30.5%) a LOR. At univariate analysis, patients with a single switch had a non-significant risk of LOR during SB2 [odds ratio (OR) = 7.86; 95% confidence interval (CI) 0.87-71, P = 0.06]. SB2-LOR was associated with previous AE under CT-P13 (OR = 9.1, 95% CI 0.82-100, P = 0.07). None of such factors was significant at multivariate analysis. Conclusion Switching from CT-P13 to SB2 seems to be safe and effective either in patients with a single than in those with multiple switches.
Published: 2020

8. A New Intraepithelial γδ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies

Author: Juha Taavela, Jorma Isola, Claudia Covelli, Angelo Andriulli, Carmela Lamacchia, Alina Popp, Paola Parente, Paolo Graziano, Markku Mäki, Tampere University, Clinical Medicine, Department of Paediatrics, and BioMediTech
Subjects: Pathology, medicine.medical_specialty, Formalin fixed paraffin embedded, Physiology, Lymphocyte, Histopathology, chemical and pharmacologic phenomena, 3121 Internal medicine, digestive system, 03 medical and health sciences, 0302 clinical medicine, Transplant surgery, medicine, Celiac disease, Diagnostics, Inflammation, T lymphocyte marker, business.industry, fungi, Gastroenterology, Disease classification, hemic and immune systems, Small bowel, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Original Article, 030211 gastroenterology & hepatology, business, tissues, Autoimmune
Abstract: Background: The histopathologic diagnosis of celiac disease (CD) may be challenging when the duodenal biopsies mucosal injury is limited. Intraepithelial T-lymphocytes (IELs) can be useful to characterize the degree of mucosal inflammation. A small fraction of IELs expresses the γδ T-cell receptor (named γδ-IELs), whose density, determined by flow cytometry or frozen section immunohistochemistry (IHC), is a specific marker for CD. Aim: To establish a new IHC assay for γδ-IELs applicable to formalin-fixed paraffin-embedded (FFPE) duodenal biopsies. Methods: We analyzed γδ-IELs using IHC in 138 duodenal biopsies using a standard IHC staining protocol with a new monoclonal antibody H-41. IELs were quantitated with digital image analysis. Results: Compared to those in non-celiac controls (n = 51), γδ-IEL density was significantly increased in newly diagnosed celiac disease patients (n = 22, p < 0.0001). In ROC-curve analysis, the cutoff of 6.5 γδ-IELs/100 enterocytes distinguished optimally active CD patients from non-celiac controls (sensitivity 96%, specificity 95%). γδ-IEL density in CD patients on a gluten-free diet (n = 53) were also higher than in controls (p < 0.0001), but lower than those in newly diagnosed CD (p < 0.0001). The diagnostic value of γδ-IELs outperformed that of CD3 + IELs in both patient groups. γδ-IELs were better than CD3 + IELs distinguishing between celiac disease and conditions histologically mimicking celiac disease (n = 12). Conclusions: Intraepithelial γδ T-lymphocytes can be stained and quantitated reliably in FFPE duodenal biopsies. The results showed excellent specificity and sensitivity for celiac disease. The new IHC method of detection of γδ-IELs is a promising addition to the routine histopathologic assessment methodology of celiac disease. publishedVersion
Published: 2020

9. The 'Hub and Spoke' model has no effect on mortality in acute upper gastrointestinal bleeding: A prospective multicenter cohort study

Author: Cristina Bucci, L. Amitrano, C. Londoni, A. Chirico, O. Triossi, A. Zambelli, F. Bazzoli, B. Germanà, F. Cipolletta, Marco Soncini, S. Mangiafico, F. Parente, E Di-Giulio, A. Andriulli, G. D'Amico, G. Baldassarre, Riccardo Marmo, A. Repici, A. Paterlini, G. Imperiali, Angelo Zullo, V Annese, F. De Nigris, R. Bennato, S. Metrangolo, L. Orsini, S. Bargiggia, I Sorrentino, M. Manno, Maria Elena Riccioni, C. Tomba, A. Nucci, A. Bizzotto, FR De-Filippo, A. Merighi, Guido Costamagna, R de-Franchis, C. Marmo, A. Anderloni, L.G. Cavallaro, P Esposito, A. Russo, R. Pumpo, D. Conte, M.A. Bianco, F Buffoli, L. Cipolletta, R. Conigliaro, P Di-Giorgio, A Filippino, G. Bresci, F Covello, P. Borgheresi, L.M. Montalbano, R.M. Zagari, E. Buscarini, Annalisa Tortora, D. Spotti, L. Ferraris, R. Lamanda, M. Franceschi, G Castrignanò, G. Spinzi, A. Lauri, S. Segato, R Grassia, V. Boarino, P. Cesaro, C De-Fanis, R. Meroni, G. Napolitano, L. Furio, AG Bonanomi, M De-Matthaeis, M. Parravicini, A Dell‘Era, L. Purita, Marmo R., Soncini M., Bucci C., Zullo A., Amitrano L., Anderloni A., Andriulli A., Annese V., Baldassarre G., Bargiggia S., Bazzoli F., Bennato R., Bianco M.A., Bizzotto A., Boarino V., Bonanomi A.G., Borgheresi P., Bresci G., Buffoli F., Buscarini E., Castrignano G., Cavallaro L.G., Cesaro P., Chirico A., Cipolletta F., Cipolletta L., Conigliaro R., Conte D., Costamagna G., Covello F., D'Amico G., De-Fanis C., De-Filippo F.R., de-Franchis R., Dell'Era A., De Nigris F., De-Matthaeis M., Di-Giorgio P., Di-Giulio E., Esposito P., Ferraris L., Filippino A., Franceschi M., Furio L., Germana' B., Grassia R., Imperiali G., Lamanda R., Lauri A., Londoni C., Mangiafico S., Manno M., Marmo C., Merighi A., Meroni R., Metrangolo S., Montalbano L.M., Napolitano G., Nucci A., Orsini L., Parente F., Parravicini M., Paterlini A., Pumpo R., Purita L., Repici A., Riccioni M.E., Russo A., Segato S., Sorrentino I., Spinzi G., Spotti D., Tortora A., Tomba C., Triossi O., Zagari R.M., and Zambelli A.
Subjects: medicine.medical_specialty, Gastrointestinal bleeding, Multivariate analysis, Organizational model, Improved survival, Comorbidity, 03 medical and health sciences, Organizational setting, 0302 clinical medicine, Health care, Spoke-hub distribution paradigm, Medicine, Humans, Hub and spoke network, Mortality, Aged, Hepatology, business.industry, Delivery of Health Care, Integrated, Gastroenterology, Acute upper gastrointestinal bleeding, Length of Stay, Middle Aged, medicine.disease, Italy, 030220 oncology & carcinogenesis, Case-Control Studies, Emergency medicine, 030211 gastroenterology & hepatology, business, Gastrointestinal Hemorrhage, Acute gastrointestinal bleeding, Cohort study
Abstract: Background: the lack of standardized pathways for patients with gastrointestinal bleeding may have led to differences in their management and inequity to medical care access. The "Hub & Spoke" model was adopted to fill this gap in many disciplines, but, to our knowledge, no data exist on its efficacy on mortality in GI bleeding. We aimed to evaluate if the "Hub & Spoke" organizational model has an impact on mortality risk from UGIB. Methods: from January 2014 to December 2015, 3324 consecutive patients admitted for UGIB in 50 Italian hospitals were enrolled (1977 patients in hospitals within the "Hub & Spoke" network for digestive hemorrhagic emergency and 1347 in hospitals outside the "Hub & Spoke" network). Clinical, endoscopic and organizational data were recorded. Results: we observed no differences in mortality between patients admitted to hospitals included or not included in the "Hub & Spoke" network (5.2% vs 6.1%, p = 0.3). On multivariate analysis, admission in gastroenterology wards (OR 0.61, p = 0.001) or an academic hospital (OR 0.65, p < 0.056) were independent protective factors while being in "Hub & Spoke" organization system did not affect mortality (OR 1.09, p = 0.57). Conclusion: the "Hub & Spoke" model per sé does not impact on mortality while being treated in academic hospital or gastroenterology wards improved survival.
Published: 2021

10. Microbiome Analysis of Mucosal Ileoanal Pouch in Ulcerative Colitis Patients Revealed Impairment of the Pouches Immunometabolites

Author: Angelo Andriulli, Fabrizio Bossa, Giuseppe Corritore, Francesco Perri, R. Fontana, Anna Latiano, Orazio Palmieri, Maria Guerra, Giuseppe Biscaglia, Tiziana Latiano, Tommaso Mazza, Stefano Castellana, Giuseppina Martino, and Anna Panza
Subjects: Adult, Male, medicine.medical_specialty, QH301-705.5, Entropy, IBD, Faecalibacterium prausnitzii, Colonic Pouches, Gut flora, Gastroenterology, Article, UC, Internal medicine, RNA, Ribosomal, 16S, medicine, Ulcerative Colitis, Humans, Microbiome, Biology (General), Intestinal Mucosa, Phylogeny, pouch, Principal Component Analysis, biology, business.industry, IPAA, Microbiota, General Medicine, Pouchitis, Biodiversity, Middle Aged, biology.organism_classification, medicine.disease, Ulcerative colitis, ulcerative colitis (UC), Metabolome, Colitis, Ulcerative, Female, Roseburia, Pouch, business, Dysbiosis, pouchitis
Abstract: The pathogenesis of ulcerative colitis (UC) is unknown, although genetic loci and altered gut microbiota have been implicated. Up to a third of patients with moderate to severe UC require proctocolectomy with ileal pouch ano-anastomosis (IPAA). We aimed to explore the mucosal microbiota of UC patients who underwent IPAA. Methods: For microbiome analysis, mucosal specimens were collected from 34 IPAA individuals. Endoscopic and histological examinations of IPAA were normal in 21 cases, while pouchitis was in 13 patients. 19 specimens from the healthy control (10 from colonic and 9 from ileum) were also analyzed. Data were analyzed using an ensemble of software packages: QIIME2, coda-lasso, clr-lasso, PICRUSt2, and ALDEx2. Results: IPAA specimens had significantly lower bacterial diversity as compared to normal. The microbial composition of the normal pouch was also decreased also when compared to pouchitis. Faecalibacterium prausnitzii, Gemmiger formicilis, Blautia obeum, Ruminococcus torques, Dorea formicigenerans, and an unknown species from Roseburia were the most uncommon in pouch/pouchitis, while an unknown species from Enterobacteriaceae was over-represented. Propionibacterium acnes and Enterobacteriaceae were the species most abundant in the pouchitis and in the normal pouch, respectively. Predicted metabolic pathways among the IPAA bacterial communities revealed an important role of immunometabolites such as SCFA, butyrate, and amino acids. Conclusions: Our findings showed specific bacterial signature hallmarks of dysbiosis and could represent bacterial biomarkers in IPAA patients useful to develop novel treatments in the future by modulating the gut microbiota through the administration of probiotic immunometabolites-producing bacterial strains and the addition of specific prebiotics and the faecal microbiota transplantation.
Published: 2021

11. Derivation and validation of Re.Co.De death score risk in patients with acute nonvariceal upper GI bleeding

Author: Riccardo Marmo, Marco Soncini, Cristina Bucci, Vincenzo Occhipinti, Lucienne Pellegrini, Angelo Zullo, Amitrano L, Andriulli A, Annese V, Baldassarre G, Bargiggia S, Balzano A, Bazzoli F, Bennato R, Bianco M A, Bizzotto A, Boarino V, Bonanomi AG, Borgheresi P, Bresci G, Buffoli F, Buscarini E, Castrignanò G, Cavallaro LG, Cesaro P, Chirico A, Cipolletta F, Cipolletta L, Conigliaro R, Conte D, Costamagna G, D’ Amico G, De Fanis C, De Filippo FR, de Franchis R, Dell‘ Era A, De Nigris F, De Matthaeis M, Di Giorgio P, Di Giulio E, Esposito P, Ferraris L, Filippino A, Franceschi M, Furio L, Germana B, Grassia R, Imperiali G, Lamanda R, Lauri A, Londoni C, Mangiafico S, Manno M, Marmo C, Meroni R, Metrangolo S, Montalbano L. M, Napolitano G, Nucci A, Orsini L, Parente F, Parravicini M, Paterlini A, Pumpo R, Purita L, Repici A, Riccioni ME, Russo A, Segato S, Sorrentino I, Spinzi G, Spotti D, Tortora A, Triossi O, Zagari RM, and Zambelli A
Subjects: Cohort Studies, Area Under Curve, Acute Disease, Gastroenterology, Humans, Radiology, Nuclear Medicine and imaging, Gastrointestinal Hemorrhage, Prognosis, Risk Assessment, Severity of Illness Index
Abstract: Scores in upper GI bleeding (UGIB) are used to stratify death risk and need for hospitalization at admission, but a tool that incorporates dynamic changes during the hospital stay is lacking. We aimed to develop a death risk score that considers changes in clinical status during hospitalization and compare its performance with existing ones.A multicenter cohort study enrolling patients with UGIB in 50 Italian hospitals from January 2014 to December 2015 was conducted. Data were collected and used to develop a risk score using logistic regression analyses. Performance curves (area under the receiver-operating characteristic [AUROC] curves), sensitivities, specificities, positive and negative predictive values, and outcomes classified as low, intermediate, and high death risk were calculated. The score's performance was externally validated and then compared with other scores.We included 1852 patients with nonvariceal UGIB in the development cohort and 912 in the validation cohorts. The new score, which we named the Re.Co.De (rebleeding-comorbidities-deteriorating) score, included 10 variables depicting the changes in clinical conditions while in the hospital. The mortality AUROC curves were .93 (95% confidence interval, .91-.96) in the derivation cohort and .94 (95% confidence interval, .91-.98) in validation cohort. In a comparison of AUROC curves with other scores, the new score showed a significant performance compared with pre- and postendoscopy scores. Patients with low and high scores had 30-day mortality rates of .001% and 48.2%, respectively.The Re.Co.De score has a higher performance for predicting mortality in patients with UGIB compared with other scores, correctly identifying patients at low and high death risk while in the hospital through a dynamic re-evaluation of clinical status.
Published: 2021

12. Germline Alterations in Patients With IBD-associated Colorectal Cancer

Author: Anna Panza, Tommaso Mazza, R. Fontana, M. Nardella, Stefano Castellana, Fabrizio Bossa, Annamaria Gentile, Orazio Palmieri, Tiziana Latiano, Angelo Andriulli, Giuseppina Martino, Francesco Perri, Giuseppe Corritore, Anna Latiano, and Giuseppe Biscaglia
Subjects: Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, Gastroenterology, Cancer, MLH1, medicine.disease, Inflammatory Bowel Diseases, digestive system diseases, Germ Cells, Crohn Disease, Dysplasia, MSH2, CDKN2A, MUTYH, Risk Factors, Internal medicine, medicine, Immunology and Allergy, Humans, Colitis, Ulcerative, business, Colorectal Neoplasms, CHEK2
Abstract: Background Patients with inflammatory bowel diseases (IBD), both ulcerative colitis (UC) and Crohn’s disease (CD), are at risk of developing a colorectal cancer (CRC). No information is available on the contribution of patients’ genetic background to CRC occurrence. This study investigates germline alterations in patients with IBD-associated CRC. Methods We profiled a panel of 39 genes potentially involved in cancer predisposition and searched for germline variants in IBD patients with CRC or high-grade dysplasia. Results After clinical exclusion of genetic cancer syndromes, 25 IBD patients (4 CD and 21 UC) with CRC or high-grade dysplasia were studied. After excluding variants with low likelihood of pathogenicity (classes 1 or 2 according the International Agency for Research on Cancer [IARC]), the panel identified pathogenic variants, likely pathogenic, or variants with unknown significance in 18 patients (72%). Six patients (24%) carried pathogenic or likely variants (IARC class 5 or 4). Of the identified variants, 4 encompassed the APC region, 3 the MLH1 gene, and the remaining ones the MSH2, MSH3, monoallelic MUTYH, EPCAM, BRCA1, CHEK2, POLD1, POLE, CDKN2A, and PDGFRA genes. Four patients carried at least 2 variants in different genes. Duration of IBD was significantly shorter in carriers of 4 or 5 IARC variants (7 years; range 0–21; P = .002) and in those with variants with unknown significance (12 years; range 0–22; P = .005) compared with patients without or with only benign variations (23.5 years; range 15–34). Conclusions In silico analysis and sequence-based testing of germline DNA from IBD patients with CRC or high-grade dysplasia detected 24% of variants positioned in pathogenic classes. In patients with type 3, 4, and 5 variants, the onset of high-grade dysplasia or CRC was significantly earlier than in patients with benign or unidentified variants. The screening for these genes could identify IBD patients requiring a more intensive endoscopic surveillance for earlier detection of dysplastic changes.
Published: 2021

13. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study

Author: Michele Barone, Antonio Massimo Ippolito, Angelo Andriulli, Ruggiero Francavilla, Francesco Pesce, Paolo Tundo, Antonio Patrizio Termite, Nicola Napoli, Pietro Gatti, Gianfranco Lauletta, Michele Milella, Endrit Shahini, A. Smedile, Vincenzo Messina, Filomena Morisco, Fabio Conti, Giuseppina Brancaccio, A. Di Leo, Teresa Santantonio, C. Masetti, Andrea Iannone, Barone, M., Iannone, A., Shahini, E., Ippolito, A. M., Brancaccio, G., Morisco, F., Milella, M., Messina, V., Smedile, A., Conti, F., Gatti, P., Santantonio, T., Tundo, Antonio, Lauletta, G., Napoli, N., Masetti, C., Termite, A. P., Francavilla, R., Di Leo, A., Pesce, F., Andriulli, A., Barone, M, Iannone, A, Shahini, E, Ippolito, A M, Brancaccio, G, Morisco, F, Milella, M, Messina, V, Smedile, A, Conti, F, Gatti, P, Santantonio, T, Tundo, P, Lauletta, G, Napoli, N, Masetti, C, Termite, A P, Francavilla, R, Di Leo, A, Pesce, F, and Andriulli, A
Subjects: Liver Cirrhosis, Male, Cirrhosis, Sofosbuvir, Sustained Virologic Response, Gastroenterology, Benzimidazole, chemistry.chemical_compound, 0302 clinical medicine, Ascites, antiviral therapy, Clinical endpoint, Prospective Studies, Chronic, Prospective cohort study, Hepatitis C, Middle Aged, Infectious Diseases, Treatment Outcome, 030220 oncology & carcinogenesis, Combination, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, medicine.symptom, medicine.drug, Human, Ledipasvir, medicine.medical_specialty, Genotype, Infectious Disease, Antiviral Agents, 03 medical and health sciences, direct-acting antivirals, hepatitis C, liver cirrhosis, Aged, Benzimidazoles, Fluorenes, Hepatitis C, Chronic, Humans, Ribavirin, Drug Therapy, Internal medicine, Virology, medicine, Antiviral Agent, direct-acting antiviral, Hepatology, business.industry, liver cirrhosi, medicine.disease, Surgery, Fluorene, Prospective Studie, chemistry, business
Abstract: The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype 1b-infected patients with cirrhosis is still under debate. Our primary endpoint was to compare the sustained virological response at post-treatment week 12 (SVR12) of sofosbuvir-ledipasvir in combination with ribavirin for 12 weeks, and sofosbuvir-ledipasvir alone for 24 weeks. This was a prospective observational study that enrolled 424 (195 naive, 229 experienced; 164 treated for 12 weeks with Ribavirin and 260 with sofosbuvir-ledipasvir alone for 24 weeks) consecutive HCV genotype 1b-infected patients with cirrhosis. The SVR12 rates were 93.9% and 99.2% in patients treated for 12 and 24 weeks, respectively (p=0.002). The baseline characteristics of patients treated for 12 weeks were significantly different from those treated for 24 weeks as regards their younger age (p=0.002), prevalence of Child-Pugh class A (p=0.002), lower MELD scores (p=0.001) and smaller number of non-responders (p=0.04). The shorter treatment was significantly associated with a lower SVR12 in univariate and multivariate analysis (p=0.007 and p=0.008, respectively). The SVR rate was unaffected by age, gender, BMI, Child-Pugh class, MELD score or previous antiviral treatment. Patients receiving ribavirin experienced more episodes of ascites and headache but less recurrence of hepatocellular carcinoma (HCC), and were prescribed more diuretics and cardiopulmonary drugs. No patient discontinued treatment. The therapeutic regimen of sofosbuvir-ledipasvir plus ribavirin administered for 12 weeks was less effective than sofosbuvir-ledipasvir alone given for 24 weeks. At odds with European guidelines, the recommended 12-week treatment with sofosbuvir-ledipasvir alone might be suboptimal for this setting of patients. This article is protected by copyright. All rights reserved.
Published: 2018

14. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

Author: Basili, S. a, Raparelli, V. b., Napoleone, L. b., Talerico, G. a., Corazza, G. R. c., Perticone, F. d., Sacerdoti, D. e., Andriulli, A. f., Licata, A. g., Pietrangelo, A., Picardi, A. i., Raimondo, G. j., Violi, F., Palasciano, G., D’Alitto, F., Palmieri, V. O., Santovito, D., Michele, Di, Croce, D., Brocco, G., Fasolato, S., Cecchetto, S., Bombonato, L., Bertoni, G., Restuccia, M., Andreozzi, T., Liguori, P., Caroleo, M. L., Perticone, B., Staltari, M., Manfredini, O., Giorgi, De, Averna, A., Giammanco, M., Granito, A., Pettinari, A., Marinelli, I., Bolondi, S., Falsetti, L., Salvi, L., Durante-Mangoni, A., Cesaro, E., Farinaro, F., Ragone, V., Morana, E., Ippolito, I., Iacobellis, A., Niro, A., Merla, G., Maimone, A., Cacciola, S., Varvara, I., Drenaggi, D., Staffolani, D., Vespasiani-Gentilucci, S., Galati, U., Gallo, G., Davì, P., Schiavone, G., Santilli, C., Tana, F., Soresi, C., Bianchi, Giovanni, Carderi, B., Pinto, I., Tuttolomondo, A., Ferrari, A., Gresele, G., Fierro, P., Morelli, T., Laffi, O., Romanelli, G., Arena, R. G., Stasi, U., Gasbarrini, A., Garcovich, M., Zocco, M. A., Riccardi, L., Ainora, M. E., Capeci, W., Martino, Giuseppe, Nobili, P., Cavallo, L., Frugiuele, M., Greco, P., Ventura, P., Cuoghi, C., Marcacci, M., Serviddio, G., Vendemiale, G., Villani, R., Gargano, R., Vidili, G., Cesare, Di, Masala, V., Delitala, M., Invernizzi, G., Vincenzo, P., Minno, Di, Tufano, G., Purrello, A., Privitera, F., Forgione, G., Curigliano, A., Senzolo, V., Rodríguez-Castro, M., Giannelli, K. I., Serra, G., Neri, C., Pignataro, S., Rizzetto, P., Debernardi, M., Svegliati, V. W., Bergamaschi, B. G., Masotti, G., Costanzo, M., Antonio, F., Angelico, F., Del, Ben, Polimeni, M., Proietti, L., Cangemi, M., Romiti, R., Toriello, G. F., Sperduti, F., Santangelo, N., Visioli, G., Todisco, G., Vestri, Anna, Farcomeni, R., Corrao, A., Gobbi, S., Corradini, E., Costantino, G., Tripepi, G., Angelico, M., Bolondi, L., D’Amico, G., Franchis, De, Gatta, R., Tassone, A., Anzaldi, E. J., Barone, M., Bazzini, M., Bianchi, C., Boari, P. I., Bracco, B., Buonauro, C., Buttà, A., Buzzetti, E., Calabria, S., Caradio, F., Carleo, P., Carrabba, Maria, Castorani, D., Cecchetto, L., Cicco, L., Cimini, S., Colombo, C., B. M., Vuono, De, Denegri, S., Del, Corso, Giosia, Di, Donnarumma, P., Giorgini, E., Grassi, P., Grembiale, D., Hijazi, A., Iamele, D., Lorusso, L., Marchese, G., Marra, Alberto, Masala, M., Miceli, M., Montebianco, G., Murgia, A. L., Naccarato, G., Padula, P., Pattoneri, D., Perego, P., Pesce, F., Petramala, P., Piano, L., Pinto, S., Pinna, D., Pignataro, M., Pretti, F. S., Pucci, V., Salinaro, G., Salzano, F., Santarossa, A., Scarpini, C., Scicali, F., Sirico, R., Suppressa, D., Talia, P., Torres, M., Traversa, D., Vazzana, M., Vecchio, Claudia, Vettore, R., Vitale, E., Basili, S., Raparelli, V., Napoleone, L., Talerico, G., Corazza, G.R., Perticone, F., Sacerdoti, D., Andriulli, A., Licata, A., Pietrangelo, A., Picardi, A., Raimondo, G., Violi, F., Palasciano, Giuseppe, D’Alitto, Felicia, Palmieri, Vincenzo Ostilio, Santovito, Daniela, Di Michele, Dario, Croce, Giuseppe, Brocco, Silvia, Fasolato, Silvano, Cecchetto, Lara, Bombonato, Giancarlo, Bertoni, Michele, Restuccia, Tea, Andreozzi, Paola, Liguori, Maria Livia, Caroleo, Benedetto, Perticone, Maria, Staltari, Orietta, Manfredini, Roberto, De Giorgi, Alfredo, Averna, Maurizio, Giammanco, Antonina, Granito, Alessandro, Pettinari, Irene, Marinelli, Sara, Bolondi, Luigi, Falsetti, Lorenzo, Salvi, Aldo, Durante-Mangoni, Emanuele, Cesaro, Flavio, Farinaro, Vincenza, Ragone, Enrico, Morana, Ignazio, Ippolito, Antonio, Iacobellis, Angelo, Niro, Grazia, Merla, Antonio, Maimone, Sergio, Cacciola, Irene, Varvara, Doriana, Drenaggi, Davide, Staffolani, Silvia, Vespasiani-Gentilucci, Umberto, Galati, Giovanni, Gallo, Paolo, Davì, Giovanni, Schiavone, Cosima, Santilli, Francesca, Tana, Claudio, Soresi, Maurizio, Bianchi Giovanni, Battista, Carderi, Isabella, Pinto, Antonio, Tuttolomondo, Antonino, Ferrari, Giovanni, Gresele, Paolo, Fierro, Tiziana, Morelli, Olivia, Laffi, Giacomo, Romanelli, Roberto Giulio, Arena, Umberto, Stasi, Cristina, Gasbarrini, Antonio, Garcovich, Matteo, Zocco, Maria Assunta, Riccardi, Laura, Ainora, Maria Elena, Capeci, William, Martino Giuseppe, Pio, Nobili, Lorenzo, Cavallo, Maurizio, Frugiuele, Pierluigi, Greco, Antonio, Ventura, Paolo, Cuoghi, Chiara, Marcacci, Matteo, Serviddio, Gaetano, Vendemiale, Gianluigi, Villani, Rosanna, Gargano, Ruggiero, Vidili, Gianpaolo, Di Cesare, Valentina, Masala, Maristella, Delitala, Giuseppe, Invernizzi, Pietro, Vincenzo, Ronca, Di Minno, Giovanni, Tufano, Antonella, Purrello, Francesco, Privitera, Graziella, Forgione, Alessandra, Curigliano, Valentina, Senzolo, Marco, Rodríguez-Castro, Kryssia Isabel, Giannelli, Gianluigi, Serra, Carla, Neri, Sergio, Pignataro, Pietro, Rizzetto, Mario, Debernardi, Venon Wilma, Svegliati, Baroni Gianluca, Bergamaschi, Gaetano, Masotti, Michela, Costanzo, Filippo, Antonio, Figliomeni, Angelico, Francesco, Del Ben, Maria, Polimeni, Licia, Proietti, Marco, Cangemi, Roberto, Romiti Giulio, Francesco, Toriello, Filippo, Sperduti, Nicolò, Santangelo, Giuseppe, Visioli, Giacomo, Todisco, Tommaso, Vestri Anna, Rita, Farcomeni, Alessio, Corrao, Salvatore, Gobbi, Paolo, Corradini, Elena, Costantino, Giorgio, Tripepi, Giovanni, Angelico, Mario, D’Amico, Gennaro, De Franchis, Roberto, Gatta, Angelo, Tassone, Eliezer Joseph, Anzaldi, Massimiliano, Barone, Milena, Bazzini, Cristina, Bianchi, Paola Ilaria, Boari, Benedetta, Bracco, Christian, Buonauro, Agostino, Buttà, Carmelo, Buzzetti, Elena, Calabria, Stefano, Caradio, Federica, Carleo, Pietro, Carrabba Maria, Domenica, Castorani, Luigi, Cicco, Sebastiano, Cimini, Claudia, Colombo, Barbara Maria, De Vuono, Stefano, Denegri, Andrea, Del Corso, Lisette, Di Giosia, Paolo, Donnarumma, Emilia, Giorgini, Paolo, Grassi, Davide, Grembiale, Alessandro, Hijazi, Daniel, Iamele, Luigi, Lorusso, Giusi, Marchese, Alessandra, Marra Alberto, Maria, Miceli, Giuseppe, Montebianco, Abenavoli Ludovico, Murgia, Giuseppe, Naccarato, Paola, Padula, Donatella, Pattoneri, Paolo, Perego, Francesca, Pesce, Paola, Petramala, Luigi, Piano, Salvatore, Pinto, Daniela, Pinna, Miriam, Pignataro, Francesca Serena, Pretti, Vincenzo, Pucci, Giacomo, Salinaro, Francesco, Salzano, Andrea, Santarossa, Claudia, Scarpini, Francesca, Scicali, Roberto, Sirico, Domenico, Suppressa, Patrizia, Talia, Michela, Torres, Daniele, Traversa, Matteo, Vazzana, Natale, Vecchio Claudia, Rita, Vettore, Elia, Vitale, Francesco, Basili, S, Raparelli, V, Napoleone, L, Talerico, G, Corazza, G, Perticone, F, Sacerdoti, D, Andriulli, A, Licata, A, Pietrangelo, A, Picardi, A, Raimondo, G, Violi, F, Palasciano, G, D'Alitto, F, Palmieri, V, Santovito, D, Di Michele, D, Croce, G, Brocco, S, Fasolato, S, Cecchetto, L, Bombonato, G, Bertoni, M, Restuccia, T, Andreozzi, P, Liguori, M, Caroleo, B, Perticone, M, Staltari, O, Manfredini, R, De Giorgi, A, Averna, M, Giammanco, A, Granito, A, Pettinari, I, Marinelli, S, Bolondi, L, Falsetti, L, Salvi, A, Durante-Mangoni, E, Cesaro, F, Farinaro, V, Ragone, E, Morana, I, Ippolito, A, Iacobellis, A, Niro, G, Merla, A, Maimone, S, Cacciola, I, Varvara, D, Drenaggi, D, Staffolani, S, Vespasiani-Gentilucci, U, Galati, G, Gallo, P, Davi, G, Schiavone, C, Santilli, F, Tana, C, Soresi, M, Bianchi Giovanni, B, Carderi, I, Pinto, A, Tuttolomondo, A, Ferrari, G, Gresele, P, Fierro, T, Morelli, O, Laffi, G, Romanelli, R, Arena, U, Stasi, C, Gasbarrini, A, Garcovich, M, Zocco, M, Riccardi, L, Ainora, M, Capeci, W, Martino Giuseppe, P, Nobili, L, Cavallo, M, Frugiuele, P, Greco, A, Ventura, P, Cuoghi, C, Marcacci, M, Serviddio, G, Vendemiale, G, Villani, R, Gargano, R, Vidili, G, Di Cesare, V, Masala, M, Delitala, G, Invernizzi, P, Vincenzo, R, Di Minno, G, Tufano, A, Purrello, F, Privitera, G, Forgione, A, Curigliano, V, Senzolo, M, Rodriguez-Castro, K, Giannelli, G, Serra, C, Neri, S, Pignataro, P, Rizzetto, M, Debernardi, V, Svegliati, B, Bergamaschi, G, Masotti, M, Costanzo, F, Antonio, F, Angelico, F, Del Ben, M, Polimeni, L, Proietti, M, Cangemi, R, Romiti, G, Toriello, F, Sperduti, N, Santangelo, G, Visioli, G, Todisco, T, Vestri Anna, R, Farcomeni, A, Corrao, S, Gobbi, P, Corradini, E, Costantino, G, Tripepi, G, Angelico, M, D'Amico, G, De Franchis, R, Gatta, A, Tassone, E, Anzaldi, M, Barone, M, Bazzini, C, Bianchi, P, Boari, B, Bracco, C, Buonauro, A, Butta, C, Buzzetti, E, Calabria, S, Caradio, F, Carleo, P, Carrabba Maria, D, Castorani, L, Cicco, S, Cimini, C, Colombo, B, De Vuono, S, Denegri, A, Del Corso, L, Di Giosia, P, Donnarumma, E, Giorgini, P, Grassi, D, Grembiale, A, Hijazi, D, Iamele, L, Lorusso, G, Marchese, A, Marra, A, Miceli, G, Montebianco, A, Murgia, G, Naccarato, P, Padula, D, Pattoneri, P, Perego, F, Pesce, P, Petramala, L, Piano, S, Pinto, D, Pinna, M, Pignataro, F, Pretti, V, Pucci, G, Salinaro, F, Salzano, A, Santarossa, C, Scarpini, F, Scicali, R, Sirico, D, Suppressa, P, Talia, M, Torres, D, Traversa, M, Vazzana, N, Vecchio Claudia, R, Vettore, E, Vitale, F, S Basili, V Raparelli, L Napoleone, G Talerico, G Corazza, F Perticone, D Sacerdoti, A Andriulli, A Licata, A Pietrangelo, A Picardi, G Raimondo, F Violi, MD on behalf of PRO-LIVER Collaborator, Palasciano Giuseppe, D’Alitto Felicia, Palmieri Vincenzo Ostilio, Santovito Daniela, Di Michele Dario, Croce Giuseppe, Brocco Silvia, Fasolato Silvano, Cecchetto Lara, Bombonato Giancarlo, Bertoni Michele, Restuccia Tea, Andreozzi Paola, Liguori Maria Livia, Caroleo Benedetto, Perticone Maria, Staltari Orietta, Manfredini Roberto, De Giorgi Alfredo, Averna Maurizio, Giammanco Antonina, Granito Alessandro, Pettinari Irene, Marinelli Sara, Bolondi Luigi, Falsetti Lorenzo, Salvi Aldo, Durante-Mangoni Emanuele, Cesaro Flavio, Farinaro Vincenza, Ragone Enrico, Morana Ignazio, Ippolito Antonio, Iacobellis Angelo, Niro Grazia, Merla Antonio, Maimone Sergio, Cacciola Irene, Varvara Doriana, Drenaggi Davide, Staffolani Silvia, Vespasiani-Gentilucci Umberto, Galati Giovanni, Gallo Paolo, Davi Giovanni, Schiavone Cosima, Santilli Francesca, Tana Claudio, Soresi Maurizio, Bianchi Giovanni Battista, Carderi Isabella, Pinto Antonio, Tuttolomondo Antonino, Ferrari Giovanni, Gresele Paolo, Fierro Tiziana, Morelli Olivia, Laffi Giacomo, Romanelli Roberto Giulio, Arena Umberto, Stasi Cristina, Gasbarrini Antonio, Garcovich Matteo, Zocco Maria Assunta, Riccardi Laura, Ainora Maria Elena, Capeci William, Martino Giuseppe Pio, Nobili Lorenzo, Cavallo Maurizio, Frugiuele Pierluigi, Greco Antonio, Ventura Paolo, Cuoghi Chiara, Marcacci Matteo, Serviddio Gaetano, Vendemiale Gianluigi, Villani Rosanna, Gargano Ruggiero, Vidili Gianpaolo, Di Cesare Valentina, Masala Maristella, Delitala Giuseppe, Invernizzi Pietro, Vincenzo Ronca, Di Minno Giovanni, Tufano Antonella, Purrello Francesco, Privitera Graziella, Forgione Alessandra, Curigliano Valentina, Senzolo Marco, Rodríguez-Castro Kryssia Isabel, Giannelli Gianluigi, Serra Carla, Neri Sergio, Pignataro Pietro, Rizzetto Mario, Debernardi Venon Wilma, Svegliati Baroni Gianluca, Bergamaschi Gaetano, Masotti Michela, Costanzo Filippo, Antonio Figliomeni, Angelico Francesco, Del Ben Maria, Polimeni Licia, Proietti Marco, Cangemi Roberto, Romiti Giulio Francesco, Toriello Filippo, Sperduti Nicolò, Santangelo Giuseppe, Visioli Giacomo, Todisco Tommaso, Vestri Anna Rita, Farcomeni Alessio, Corrao Salvatore, Gobbi Paolo, Corradini Elena, Costantino Giorgio, Tripepi Giovanni, Angelico Mario, D’Amico Gennaro, de Franchis Roberto, Gatta Angelo, Tassone Eliezer Joseph, Anzaldi Massimiliano, Barone Milena, Bazzini Cristina, Bianchi Paola Ilaria, Boari Benedetta, Bracco Christian, Buonauro Agostino, Buttà Carmelo, Buzzetti Elena, Calabria Stefano, Caradio Federica, Carleo Pietro, Carrabba Maria Domenica, Castorani Luigi, Cicco Sebastiano, Cimini Claudia, Colombo Barbara Maria, De Vuono Stefano, Denegri Andrea, Del Corso Lisette, Di Giosia Paolo, Donnarumma Emilia, Giorgini Paolo, Grassi Davide, Grembiale Alessandro, Hijazi Daniel, Iamele Luigi, Lorusso Giusi, Marchese Alessandra, Marra Alberto Maria, Miceli Giuseppe, Montebianco Abenavoli Ludovico, Murgia Giuseppe, Naccarato Paola, Padula Donatella, Pattoneri Paolo, Perego Francesca, Pesce Paola, Petramala Luigi, Piano Salvatore, Pinto Daniela, Pinna Miriam, Pignataro Francesca Serena, Pretti Vincenzo, Pucci Giacomo, Salinaro Francesco, Salzano Andrea, Santarossa Claudia, Scarpini Francesca, Scicali Roberto, Sirico Domenico, Suppressa Patrizia, Talia Michela, Torres Daniele, Traversa Matteo, Vazzana Natale, Vecchio Claudia Rita, Vettore Elia, Vitale Francesco, Corazza, G. R., Guidacci, Raimondo, Palasciano, G., D'Alitto, F., Palmieri, V. O., Santovito, D., Di Michele, D., Croce, G., Brocco, S., Fasolato, S., Cecchetto, L., Bombonato, G., Bertoni, M., Restuccia, T., Andreozzi, P., Liguori, M. L., Caroleo, B., Perticone, M., Staltari, O., Manfredini, R., De Giorgi, A., Averna, M., Giammanco, A., Granito, A., Pettinari, I., Marinelli, S., Bolondi, L., Falsetti, L., Salvi, A., Durante-Mangoni, E., Cesaro, F., Farinaro, V., Ragone, E., Morana, I., Ippolito, A., Iacobellis, A., Niro, G., Merla, A., Maimone, S., Cacciola, I., Varvara, D., Drenaggi, D., Staffolani, S., Vespasiani-Gentilucci, U., Galati, G., Gallo, P., Davi, G., Schiavone, C., Santilli, F., Tana, C., Soresi, M., Bianchi Giovanni, B., Carderi, I., Pinto, A., Tuttolomondo, A., Ferrari, G., Gresele, P., Fierro, T., Morelli, O., Laffi, G., Romanelli, R. G., Arena, U., Stasi, C., Gasbarrini, A., Garcovich, M., Zocco, M. A., Riccardi, L., Ainora, M. E., Capeci, W., Martino Giuseppe, P., Nobili, L., Cavallo, M., Frugiuele, P., Greco, A., Ventura, P., Cuoghi, C., Marcacci, M., Serviddio, G., Vendemiale, G., Villani, R., Gargano, R., Vidili, G., Di Cesare, V., Masala, M., Delitala, G., Invernizzi, P., Vincenzo, R., Di Minno, G., Tufano, A., Purrello, F., Privitera, G., Forgione, A., Curigliano, V., Senzolo, M., Rodriguez-Castro, K. I., Giannelli, G., Serra, C., Neri, S., Pignataro, P., Rizzetto, M., Debernardi, V. W., Svegliati, B. G., Bergamaschi, G., Masotti, M., Costanzo, F., Antonio, F., Angelico, F., Del Ben, M., Polimeni, L., Proietti, M., Cangemi, R., Romiti, G. F., Toriello, F., Sperduti, N., Santangelo, G., Visioli, G., Todisco, T., Vestri Anna, R., Farcomeni, A., Corrao, S., Gobbi, P., Corradini, E., Costantino, G., Tripepi, G., Angelico, M., D'Amico, G., De Franchis, R., Gatta, A., Tassone, E. J., Anzaldi, M., Barone, M., Bazzini, C., Bianchi, P. I., Boari, B., Bracco, C., Buonauro, A., Butta, C., Buzzetti, E., Calabria, S., Caradio, F., Carleo, P., Carrabba Maria, D., Castorani, L., Cicco, S., Cimini, C., Colombo, B. M., De Vuono, S., Denegri, A., Del Corso, L., Di Giosia, P., Donnarumma, E., Giorgini, P., Grassi, D., Grembiale, A., Hijazi, D., Iamele, L., Lorusso, G., Marchese, A., Marra, A. M., Miceli, G., Montebianco, A. L., Murgia, G., Naccarato, P., Padula, D., Pattoneri, P., Perego, F., Pesce, P., Petramala, L., Piano, S., Pinto, D., Pinna, M., Pignataro, F. S., Pretti, V., Pucci, G., Salinaro, F., Salzano, A., Santarossa, C., Scarpini, F., Scicali, R., Sirico, D., Suppressa, P., Talia, M., Torres, D., Traversa, M., Vazzana, N., Vecchio Claudia, R., Vettore, E., and Vitale, F.
Subjects: Liver Cirrhosis, Male, Settore MED/09 - Medicina Interna, 030204 cardiovascular system & hematology, Gastroenterology, Severity of Illness Index, cjirrhosis, ACTIVATION, 0302 clinical medicine, Risk Factors, Medicine, Platelet, Prospective Studies, Prospective cohort study, RISK, Aged, 80 and over, medicine.diagnostic_test, PRO-LIVER, Platelet, cirrhosis, gastrointestinal bleeding, ASSOCIATION, Middle Aged, Prognosis, Italy, 030211 gastroenterology & hepatology, Female, Gastrointestinal Hemorrhage, Human, Adult, Platelets, medicine.medical_specialty, Prognosi, Liver Cirrhosi, MEDLINE, COAGULATION, gastrointestinal bleeding, Socio-culturale, Hemorrhage, Hepatology, Follow-Up Studie, 03 medical and health sciences, Text mining, Internal medicine, Severity of illness, ENDOTOXEMIA, Pro-Liver Study, Humans, HEMOSTASIS, International Normalized Ratio, Aged, Proportional Hazards Models, Prothrombin time, Cirrhosi, Platelet Count, Bleeding, Liver Cirrhosis, business.industry, Proportional hazards model, Platelet Count, Risk Factor, cirrhosis, bleeding, Thrombocytopenia, Prospective Studie, THROMBOSIS, Platelets, cjirrhosis, bleeding, PRO-LIVER, Proportional Hazards Model, Prothrombin Time, business, DECOMPENSATED CIRRHOSIS, Follow-Up Studies
Abstract: OBJECTIVES: Thrombocytopenia is a hallmark for patients with cirrhosis and it is perceived as a risk factor for bleeding events. However, the relationship between platelet count and bleeding is still unclear. METHODS: We investigated the relationship between platelet count and major or clinical relevant nonmajor bleedings during a follow-up of â¼4 years. RESULTS: A total of 280 cirrhotic patients with different degrees of liver disease (67% males; age 64Â±37 years; 47% ChildâPugh B and C) were followed up for a median of 1,129 (interquartile range: 800â1,498) days yielding 953.12 patient-year of observation. The annual rate of any significant bleeding was 5.45%/year (3.57%/year and 1.89%/year for major and minor bleeding, respectively). Fifty-two (18.6%) patients experienced a major (n=34) or minor (n=18) bleeding event, predominantly from gastrointestinal origin. Platelet counts progressively decreased with the worsening of liver disease and were similar in patients with or without major or minor bleeding: a platelet count â¤50Ã103/Î¼l was detected in 3 (6%) patients with and in 20 (9%) patients without any bleeding event. Conversely, prothrombin time-international normalized ratio was slightly higher in patients with overall or major bleeding. On Cox proportional hazard analysis, only a previous gastrointestinal bleeding (hazard ratio (HR): 1.96; 95% confidence interval: 1.11â3.47; P=0.020) and encephalopathy (HR: 2.05; 95% confidence interval: 1.16â3.62; P=0.013) independently predicted overall bleeding events. CONCLUSIONS: Platelet count does not predict unprovoked major or minor bleeding in cirrhotic patients.
Published: 2018

15. Identification of recessively inherited genetic variants for pancreatic cancer risk

Author: Pavel Soucek, Viktor Hlavac, Markus K. Diener, Daniela Basso, Beatrice Mohelnikova-Duchonova, Balázs Németh, Herman Brenner, Roberto Salvia, Vytautas Kiudelis, Konstantinos Papiris, Domenica Gioffreda, Manuel Gentiluomo, Raffaele Pezzilli, János Novák, Oliver Strobel, Martin Oliverius, Martin Lovecek, John P. Neoptolemos, Paolo Giorgio Arcidiacono, Maria Chiara Petrone, Rita T. Lawlor, Ugo Boggi, Ye Lu, Federico Canzian, Yogesh K. Vashist, Livia Archibugi, Stefano Landi, Krzysztof Jamroziak, Cosimo Sperti, Faik G. Uzunoglu, Pavel Vodicka, Stefania Moz, Andrea Mambrini, Andrea Szentesi, Dezso Kelemen, Maurizio Lucchesi, Péter Hegyi, Gabriele Capurso, Giulia Martina Cavestro, Zdenek Kala, Renata Talar-Wojnarowska, Roger Chammas, Hanneke W. M. van Laarhoven, Luca Morelli, George Theodoropoulos, Mateus Nóbrega Aoki, Daniele Campa, Giuseppe Vanella, Thilo Hackert, Angelo Andriulli, Anna Caterina Milanetto, Sabrina Gloria Giulia Testoni, Xin Gao, Ewa Małecka-Panas, Laura Ginocchi, Marta Puzzono, Angelica Macauda, Olivier R. Busch, Ondrej Strouhal, Audrius Ivanauskas, Bas Bueno-de-Mesquita, Jakob R. Izbicki, William Greenhalf, Silvia Carrara, Francesca Tavano, Feng Guo, Maria Gazouli, Stefano Ermini, and Juozas Kupcinskas
Subjects: Genetics, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Pancreatic cancer, Gastroenterology, Genetic variants, medicine, Identification (biology), medicine.disease, business
Published: 2021

16. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis

Author: Antonino Carlo Privitera, Antonio Rispo, C. Ferracane, Maria Cappello, Raffaele Melina, Francesco William Guglielmi, Angelo Andriulli, Rocco Spagnuolo, Fabrizio Bossa, Giuseppe Costantino, M. Mendolaro, Mariabeatrice Principi, Agnese Miranda, Pietro Paese, Alessandro Azzarone, Ladislava Sebkova, Silvia Mazzuoli, Olga Maria Nardone, R. Clemente, Antonio Tursi, Marco Romano, M. Patturelli, A. Lauria, Endrit Shahini, C. Ricciardelli, Caterina Sgarro, L. Fanigliulo, Laurino Grossi, Gabriele Riegler, Walter Fries, Giuseppe Pranzo, Nello Buccianti, Gaetano Inserra, Giuseppe Biscaglia, Maria Rosa Valvano, Bossa, F, Biscaglia, G, Valvano, Mr, Costantino, G, Lauria, A, Clemente, R, Ferracane, C, Shahini, E, Mendolaro, M, Grossi, L, Mazzuoli, S, Rispo, A, Pranzo, G, Sebkova, L, Tursi, A, Miranda, A, Patturelli, M, Spagnuolo, R, Ricciardelli, C, Sgarro, C, Paese, P, Inserra, G, Azzarone, A, Nardone, O, Fries, W, Buccianti, N, Privitera, Ac, Principi, Mb, Cappello, M, Guglielmi, Fw, Romano, M, Riegler, G, Fanigliulo, L, Melina, R, and Andriulli, A.
Subjects: Adult, Male, medicine.medical_specialty, Multivariate analysis, Physiology, Biologics, Inflammatory bowel disease, Golimumab, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Autoinjector, Internal medicine, Medicine, Humans, Adverse effect, Dose-Response Relationship, Drug, business.industry, Gastroenterology, Anti-TNF-alpha, Ulcerative colitis, Antibodies, Monoclonal, Hepatology, Middle Aged, medicine.disease, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Calprotectin, business, medicine.drug
Abstract: Golimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis. To assess the short- and long-term effectiveness and safety of golimumab in daily clinical practice and to identify predictors of response. Consecutive patients treated with golimumab in 22 Italian centers were enrolled. Clinical, laboratory, and endoscopic data were prospectively collected before and during treatment. A subgroup of patients completed a questionnaire to assess personal satisfaction with a golimumab autoinjector system. A total of 196 patients were included. After 3 months, 130 patients were responders (66.3%) and showed significant reductions in mean partial, total, and endoscopic Mayo scores and in mean ESR, C-reactive protein, and fecal calprotectin levels (p
Published: 2019

17. microRNA-mRNA network model in patients with achalasia

Author: Angelo Andriulli, Orazio Palumbo, Giuseppe Corritore, Tommaso Mazza, Anna Panza, Domenica Gioffreda, Tommaso Biagini, Anna Latiano, Fabrizio Bossa, Gabrio Bassotti, Orazio Palmieri, Salvatore Tolone, Tiziana Latiano, Massimo Carella, Antonio Merla, Giuseppina Martino, Antonello Cuttitta, Palmieri, O., Mazza, T., Bassotti, G., Merla, A., Tolone, S., Biagini, T., Cuttitta, A., Bossa, F., Martino, G., Latiano, T., Corritore, G., Gioffreda, D., Palumbo, O., Carella, M., Panza, A., Andriulli, A., and Latiano, A.
Subjects: Male, 0301 basic medicine, Physiology, mRNA, Achalasia, Disease, Computational biology, Biology, 03 medical and health sciences, 0302 clinical medicine, Immune system, microRNA, medicine, Humans, Gene Regulatory Networks, Digital polymerase chain reaction, RNA, Messenger, ROCK2, Gene, achalasia, expression profile, Endocrine and Autonomic Systems, Gastroenterology, medicine.disease, Esophageal Achalasia, MicroRNAs, 030104 developmental biology, 030220 oncology & carcinogenesis, Gene chip analysis, Female, Transcriptome
Abstract: Background: Achalasia is a rare idiopathic disease with a complex etio-pathogenesis still unknown. This study aimed to identify microRNA (miRNA)-mRNA regulatory networks underlying achalasia. Methods: The investigation was performed in tissue specimens from 11 patients and five controls using the microarray technology followed by an integrated bioinformatics analysis. Key Results: One hundred and six miRNAs were significantly up-regulated and 64 were down-regulated in achalasia patients. The expression of the most 10 differential expressed miRNAs (miR-122-5p, miR-133a-3p, miR-504-5p, miR-187-3p, miR-133b, miR-200c-3p, miR-375, miR-200b-5p, miR-200b-3p, and miR203a) was confirmed by droplet digital PCR in an independent cohort. The interactions between the significant miRNAs and their targets uncovered 14 miRNA-mRNA interacting pairs with experimentally predicted genes (ie, FN1, ROCK2, DPYSL2), and 35 pairs with not experimentally target genes (ie, SULF1, MRVI1, PRKG1); all genes were involved in immune cell trafficking, skeletal and muscular system development, nervous system development macro-processes. Conclusion & Inferences: The mRNA–miRNA regulatory networks described in this study provide new insights in the genetic background of the disease, suggesting further investigations in novel pathogenic mechanisms.
Published: 2019

18. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

Author: Anna Latiano, M.R. D'Altilia, Giuseppe Corritore, Fabrizio Bossa, A. Marseglia, Sonia Carparelli, Francesca Tavano, Giuseppina Martino, Fulvia Terracciano, Anna Panza, Angelo Andriulli, M. Nardella, Maria Pastore, Francesco Perri, Orazio Palmieri, Michele Sacco, Maria Guerra, and Tiziana Latiano
Subjects: Male, Antibodies, Viral, Inflammatory bowel disease, 0302 clinical medicine, Crohn Disease, Seroepidemiologic Studies, skin and connective tissue diseases, Child, Aged, 80 and over, Alimentary Tract, Gastroenterology, Antibodies, Monoclonal, Middle Aged, Ulcerative colitis, Thalidomide, Hospitalization, Italy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, Ustekinumab, Immunosuppressive Agents, medicine.drug, Biologic therapy, Adult, medicine.medical_specialty, Adolescent, IBD, Enzyme-Linked Immunosorbent Assay, Antibodies, Monoclonal, Humanized, Vedolizumab, COVID-19 Serological Testing, 03 medical and health sciences, Young Adult, Gastrointestinal Agents, Internal medicine, medicine, Adalimumab, Humans, Risk factor, Aged, Biological Products, Hepatology, business.industry, SARS-CoV-2, COVID-19, medicine.disease, Inflammatory Bowel Diseases, Infliximab, Golimumab, Colitis, Ulcerative, business
Abstract: Background Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs. Methods Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing. Results Two hundred and fifty-nine patients (27 children) with a mean age of 42.2 ± 16.7 years (range 9 - 88) and a mean duration of disease of 13.4 ± 10 years (range 0.2 – 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn's disease. About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%). Conclusions In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.
Published: 2020

19. Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry

Author: Sergio Segato, Mario Grassini, A. Maurano, Matteo Bosani, Antonio Colecchia, Martina Cargiolli, Giovanni Barbara, Antonio Maria Morselli Labate, Ennio Guido, Cesare Cremon, Giuseppe Biscaglia, Marilia Carabotti, Donato Iuliano, E. Galliani, Davide Festi, Bruno Annibale, Biagio Mauro, Alida Andrealli, S. Bargiggia, Carola Severi, R. Reati, Maria Antonia Bianco, Matteo Neri, Santino Marchi, Rosario Cuomo, Francesca Falangone, Agostino Di Ciaula, Franco Iafrate, Simona Bartolozzi, Paolo Andreozzi, Bastianello Germanà, Alessandro Moscatelli, Marco Pennazio, Andrea Laghi, Marco Astegiano, Riccardo Nascimbeni, S. Peralta, Maria Erminia Bottiglieri, Paolo Usai, Piero Portincasa, Carolina Ciacci, Paola Iovino, Pietro Occhipinti, Vincenzo Savarino, Fabio Pace, Alessandro Redaelli, Giovanni Latella, Franco Radaelli, V. Festa, Mirko Di Ruscio, Giuseppe Scaccianoce, Marco Rossi, Marco Dinelli, Francesco Bachetti, Valentina Valle, Angelo Andriulli, M. Parravicini, Marina De Matthaeis, Raffale Salerno, Clara Virgilio, Elisa Marabotto, Sandro Ardizzone, Gian Andrea Binda, Alessandra Dell'Era, Giampiero Manes, Gabrio Bassotti, Carabotti M., Morselli Labate A.M., Cremon C., Cuomo R., Pace F., Andreozzi P., Falangone F., Barbara G., and Annibale B.
Subjects: Adult, Male, medicine.medical_specialty, Diverticular complications, digestive system, Pathogenesis, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, In patient, Prospective Studies, Registries, Family history, Life Style, Diverticulitis, Aged, Aged, 80 and over, Diverticular Diseases, Hepatology, Acute diverticulitis, business.industry, digestive, oral, and skin physiology, Gastroenterology, Middle Aged, medicine.disease, Diverticular diseases, digestive system diseases, surgical procedures, operative, Logistic Models, Italy, 030220 oncology & carcinogenesis, Diverticular complication, Diverticular disease, 030211 gastroenterology & hepatology, Observational study, Female, business, Cohort study
Abstract: Background Pathogenesis of acute diverticulitis and diverticular bleeding remains poorly defined, and few data compare directly risk factors for these complications. Aims to assess differences in clinical features, lifestyles factors and concurrent drug use in patients with acute diverticulitis and those with diverticular bleeding. Methods Data were obtained from the REMAD Registry, an ongoing 5-year prospective, observational, multicenter, cohort study conducted on 1,217 patients. Patient- and clinical- related factors were compared among patients with uncomplicated diverticular disease, patients with previous acute diverticulitis, and patients with previous diverticular bleeding. Results Age was significantly lower (OR 0.48, 95% CI: 0.34–0.67) and family history of diverticular disease was significantly higher (OR 1.60, 95% CI: 1.11–2.31) in patients with previous diverticulitis than in patients with uncomplicated diverticular disease, respectively. Chronic obstructive pulmonary disease was significantly higher in patients with previous diverticular bleeding as compared with both uncomplicated diverticular disease (OR 8.37, 95% CI: 2.60–27.0) and diverticulitis (OR 4.23, 95% CI: 1.11–16.1). Conclusion This ancillary study from a nationwide Registry showed that some distinctive features identify patients with acute diverticulitis and diverticular bleeding. These information might improve the assessment of risk factors for diverticular complications.
Published: 2020

20. Associations between pancreatic expression quantitative trait loci (eQTLs) and pancreatic ductal adenocarcinoma risk

Author: Paolo Giorgio Arcidiacono, Herman Brenner, Oliver Strobel, Beatrice Mohelnikova-Duchonova, Martin Lovecek, Angelica Macauda, Laura Pistoni, Krzysztof Jamroziak, Luca Pollina, Milena Di Leo, Maria Gazouli, Giulia Martina Cavestro, Emanuele Federico Kauffmann, George Theodoropoulos, Giuseppe Vanella, Jakob R. Izbicki, Edita Kreivėnaitė, Gabriele Capurso, Martin Oliverius, Viktor Hlavac, Domenica Gioffreda, Maria Chiara Petrone, Angelo Andriulli, Livia Archibugi, Raffaele Pezzilli, Ludmila Vodickova, Sabrina Gloria Giulia Testoni, Cosimo Sperti, Audrius Ivanauskas, Michael F. Nentwich, Pavel Vodicka, Daniela Basso, Renata Talar-Wojnarowska, Daniele Campa, Giulia Peduzzi, Thilo Hackert, John P. Neoptolemos, Dania Bozzato, Andrea Szentesi, Péter Hegyi, Federico Canzian, Manuel Gentiluomo, Giuseppe Malleo, Erika Darvasi, Juozas Kupcinskas, Ye Lu, Anna Caterina Milanetto, Pavel Soucek, László Gajdán, Cristian Gheorghe, Luca Morelli, Francesca Tavano, Stefano Landi, Raffaella Alessia Zuppardo, Rita T. Lawlor, and Yogesh K. Vashist
Subjects: Pancreatic ductal adenocarcinoma, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Expression quantitative trait loci, Gastroenterology, Cancer research, Medicine, business
Published: 2020

21. Polymorphic variants within non-coding RNA and risk of pancreatic ductal adenocarcinoma

Author: Raffaella Alessia Zuppardo, Maria Gazouli, Thilo Hackert, Claudio Pasquali, Yogesh K. Vashist, Ye Lu, John P. Neoptolemos, Luca Morelli, Audrius Ivanauskas, Edita Kreivenaite, Sabrina Gloria Giulia Testoni, Cristian Gheorghe, Ewa Małecka-Panas, Francesca Tavano, Andrea Szentesi, Paolo Giorgio Arcidiacono, Martin Oliverius, Klara Cervena, Maria Chiara Petrone, Erika Darvasi, Péter Hegyi, Stefania Moz, Juozas Kupcinskas, Daniele Campa, George Theodoropoulos, Stefano Landi, Cosimo Sperti, Federico Canzian, Matteo Giaccherini, Gabriele Capurso, Raffaele Pezzilli, Beatrice Mohelnikova-Duchonova, Chiara Corradi, Claudio Luchini, Null Archibugi ., Michael F. Nentwich, Pavel Vodicka, Giuseppe Vanella, Domenica Gioffreda, Niccolò Napoli, Viktor Hlavac, Giulia Martina Cavestro, G. Di Franco, Anna Caterina Milanetto, Pavel Soucek, László Gajdán, Silvia Carrara, H Brenner, Manuel Gentiluomo, Krzysztof Jamroziak, Rita T. Lawlor, Angelo Andriulli, Jakob R. Izbicki, and Oliver Strobel
Subjects: Pancreatic ductal adenocarcinoma, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Gastroenterology, Cancer research, Medicine, business, Non-coding RNA
Published: 2020

22. Inverted colonic diverticulum (ICD): report of two cases and literature review of a not that unusual endoscopic challenge

Author: Sonia Carparelli, Arcangela Patrizia Giuliani, Paola Parente, Francesco Perri, Giuseppe Biscaglia, Angelo Andriulli, Rossella Cubisino, Fabrizio Bossa, Francesco Cocomazzi, and M. Gentile
Subjects: medicine.medical_specialty, medicine.medical_treatment, Perforation (oil well), Colonoscopy, Diverticulum, Colon, Lesion, 03 medical and health sciences, Therapeutic approach, 0302 clinical medicine, Biopsy, medicine, Humans, Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Endoscopy, medicine.disease, digestive system diseases, Polypectomy, Dysplasia, 030220 oncology & carcinogenesis, Diverticular disease, 030211 gastroenterology & hepatology, Radiology, medicine.symptom, business
Abstract: Inverted colonic diverticulum (ICD) is a rare intraluminal lesion occurring in about 0.7-1.7% of people, often endoscopically indistinguishable from polyps. Some unspecific endoscopic features may assist to distinguish polypoid ICD from true polyps. This differentiation bears relevance for the therapeutic approach, as colonic polyps require snare polypectomy, a practice which may be associated with colonic perforation in case of true ICD. The endoscopist, therefore, should be aware of the likelihood of detecting these lesions during colonoscopy. A close inspection and a gentle probing could assist in a correct diagnosis and avoid risky procedures such as biopsy or polypectomy. Rarely, a neoplasm arising over an ICD and its treatment has been described. We reported two cases, one of which with dysplasia, and their treatment, and reviewed all the ICD endoscopic cases so far reported in the literature, remarking the possibility of finding pedunculated ICDs or neoplasm arising over an ICD.
Published: 2021

23. Etiological factors of chronic hepatitis in Italy: a 2014 national survey

Author: Antonina Smedile, Angelo Andriulli, Caterina Sagnelli, Floriano Rosina, Giovanni Battista Gaeta, Mariantonietta Pisaturo, Evangelista Sagnelli, Massimo De Luca, Piero Luigi Almasio, Coppola N, Maurizio Russello, Mario Pirisi, Tommaso Stroffolini, Stroffolini, T., Sagnelli, E., Almasio, P. L., Andriulli, A., Smedile, A., Pirisi, M., Sagnelli, C., Russello, M., Coppola, N., De Luca, M., Pisaturo, M., Rosina, F., Gaeta, G. B., Stroffolini, T, Sagnelli, Evangelista, Almasio, Pl, Andriulli, A, Smedile, A, Pirisi, M, Sagnelli, Caterina, Russello, M, Coppola, Nicola, DE LUCA, Marino, Pisaturo, M, Rosina, F, Gaeta, Giovanni Battista, Stroffolini T., Sagnelli E., Almasio P.L., Andriulli A., Smedile A., Pirisi M., Sagnelli C., Russello M., Coppola N., De Luca M., Pisaturo M., Rosina F., and Gaeta G.B.
Subjects: nonalcoholic fatty liver disease, Adult, Male, medicine.medical_specialty, Pediatrics, Time Factors, Time Factor, Adolescent, Hepatitis C virus, medicine.disease_cause, metabolic syndrome, 03 medical and health sciences, Young Adult, 0302 clinical medicine, chronic hepatiti, Risk Factors, Epidemiology, Nonalcoholic fatty liver disease, medicine, Prevalence, Humans, Aged, Hepatitis, Chronic, Hepatitis, Aged, 80 and over, Hepatology, business.industry, Risk Factor, Gastroenterology, Entecavir, Hepatitis C, Health Survey, Hepatitis B, Hepatitis C, Chronic, Middle Aged, medicine.disease, Health Surveys, Italy, 030220 oncology & carcinogenesis, Etiology, 030211 gastroenterology & hepatology, Female, hepatitis C virus infection, business, Human, medicine.drug
Abstract: Background The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. Aim The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. Patients and methods Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed. Results The mean age of the patients was 58.3 years, with a sex ratio (male/female) of 1.5. HCV infection (also with other etiologies) continues to be the most prevalent etiology (58.1%). However, this prevalence was lower (P
Published: 2017

24. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

Author: Piero Luigi Almasio, Filomena Morisco, Caterina Furlan, Tommaso Stroffolini, Caterina Sagnelli, Nicola Coppola, Angelo Andriulli, Evangelista Sagnelli, Antonina Smedile, Stroffolini, T., Sagnelli, E., Sagnelli, C., Smedile, A., Furlan, C., Morisco, F., Coppola, N., Andriulli, A., Almasio, P. L., Stroffolini, Tommaso, Sagnelli, Evangelista, Sagnelli, Caterina, Smedile, Antonina, Furlan, Caterina, Morisco, Filomena, Coppola, Nicola, Andriulli, Angelo, Almasio, Piero Luigi, and Almasio P.L.
Subjects: Adult, Liver Cirrhosis, Male, Hepatitis B virus, medicine.medical_specialty, HBsAg, Cirrhosis, HBV reactivation, Hbv markers, Hbv reactivation, Prevalence, Hbv vaccination, Hepacivirus, Chronic liver disease, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Hepatitis B Antibodies, Reimbursement, Aged, Hepatitis B Surface Antigens, Hepatology, Coinfection, business.industry, Gastroenterology, HCV therapy, virus diseases, Hepatitis C, Chronic, Middle Aged, Hepatitis B, medicine.disease, Chronic HCV infection, HBV/HCV coinfection, digestive system diseases, Italy, 030220 oncology & carcinogenesis, DNA, Viral, Female, Virus Activation, 030211 gastroenterology & hepatology, business
Abstract: Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, isolated anti-HBc and anti-HBc/anti-HBs-positivity were 2.9%, 8.1% and 14.7%, respectively. Among the estimated one million HCV-RNA-positive subjects in Italy, a substantial number of subjects are at risk of HBV reactivation due to DAA therapy. The prevalence of liver cirrhosis was higher than that of CLD in HBsAg-positive subjects (4.4% vs. 2.6%, p < 0.01) but not in those positive for other HBV markers. Conclusions: These findings outline the burden of HBV markers among HCV-RNA-positive subjects in Italy, where in 2017 reimbursement for DAA therapy by the National Health System became universal for all patients with chronic HCV infection. HBV vaccination coverage should be greatly extended, since nearly two thirds of subjects in this study resulted negative for any HBV marker.
Published: 2017

25. Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

Author: Tommaso Stroffolini, Evangelista Sagnelli, Angelo Andriulli, Guido Colloredo, Caterina Furlan, Giovanni Battista Gaeta, Filomena Morisco, Mario Pirisi, Floriano Rosina, Caterina Sagnelli, Antonina Smedile, Piero Luigi Almasio, EPACRON study group, Stroffolini, Tommaso, Sagnelli, Evangelista, Andriulli, Angelo, Colloredo, Guido, Furlan, Caterina, Gaeta, Giovanni Battista, Morisco, Filomena, Pirisi, Mario, Rosina, Floriano, Sagnelli, Caterina, Smedile, Antonina, Almasio, Piero Luigi, Stroffolini T., Sagnelli E., Andriulli A., Colloredo G., Furlan C., Gaeta G.B., Morisco F., Pirisi M., Rosina F., Sagnelli C., Smedile A., and Almasio P.L.
Subjects: Genetics and Molecular Biology (all), 0301 basic medicine, Liver Cirrhosis, RNA viruses, Male, Chronic Hepatitis, Cirrhosis, lcsh:Medicine, Alcohol abuse, Hepacivirus, Sex Factor, Chronic liver disease, medicine.disease_cause, Biochemistry, Gastroenterology, Chronic Liver Disease, 0302 clinical medicine, Risk Factors, Medicine and Health Sciences, lcsh:Science, Pathology and laboratory medicine, Multidisciplinary, Alcohol Consumption, Hepatitis C virus, Liver Diseases, Fatty liver, virus diseases, Hepatitis C, Hepatitis B, Medical microbiology, Middle Aged, Oncology, Viruses, Coinfection, 030211 gastroenterology & hepatology, Female, Pathogens, Research Article, Human, Adult, medicine.medical_specialty, Hepatitis B virus, Alcohol Drinking, Liver Cirrhosi, Gastroenterology and Hepatology, Microbiology, Carcinomas, 03 medical and health sciences, Sex Factors, Internal medicine, Gastrointestinal Tumors, medicine, Humans, Nutrition, Aged, Biochemistry, Genetics and Molecular Biology (all), Flaviviruses, business.industry, Risk Factor, lcsh:R, Organisms, Viral pathogens, Biology and Life Sciences, Cancers and Neoplasms, Hepatocellular Carcinoma, medicine.disease, Virology, digestive system diseases, Hepatitis viruses, Agricultural and Biological Sciences (all), Diet, Microbial pathogens, Fatty Liver, 030104 developmental biology, lcsh:Q, business
Abstract: Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysis. Results Females were older than males (p
Published: 2017

26. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

Author: A. Armuzzi, Silvio Danese, Maurizio Vecchi, Fabiana Castiglione, Gianmichele Meucci, Gionata Fiorino, M. Di Girolamo, Natalia Manetti, Sandro Ardizzone, Simone Saibeni, A. Ronchetti, Sara Renna, Giovanni Maconi, Agostino Colli, Giulia Rizzuto, Anna Kohn, Paolo Lionetti, Silvia Ghione, Angela Variola, Agostino Ventra, O. Nardone, Stefano Milani, Silvia Mazzuoli, Maria M. Terpin, Renata D'Incà, V. F. Annese, A. Di Sabatino, A. Orlando, Francesco Perri, Andrea Cassinotti, R. Salerno, Arnaldo Amato, Daniela Pugliese, Lorenzo Bertani, A. Geccherle, S. Saettone, Francesco William Guglielmi, Angelo Andriulli, Francesca Rogai, Fabrizio Bossa, Claudio Camillo Cortelezzi, L. Caserta, E. Troncone, Livia Biancone, Francesco Costa, R. Tari, M. Bosani, Alessandro Massari, Arianna Massella, Maria Cappello, B. Scrivo, Walter Fries, Maria Laura Annunziata, Mariabeatrice Principi, Cristina Bezzio, Laura Cantoro, M.C. Parodi, Gianni Imperiali, Carlo Petruzzellis, Greta Lorenzon, G. Martino, Luisa Guidi, A. Bertani, Armuzzi, Alessandro, Fiorino, Gionata, Variola, Angela, Manetti, Natalia, Fries, Walter, Orlando, Ambrogio, Maconi, Giovanni, Bossa, Fabrizio, Cappello, Maria, Biancone, Livia, Cantoro, Laura, Costa, Francesco, D'Incà, Renata, Lionetti, Paolo, Principi, Mariabeatrice, Castiglione, Fabiana, Annunziata, Maria L, Di Sabatino, Antonio, Di Girolamo, Maria, Terpin, Maria M, Cortelezzi, Claudio C, Saibeni, Simone, Amato, Arnaldo, Ardizzone, Sandro, Guidi, Luisa, Danese, Silvio, Massella, Arianna, Ventra, Agostino, Rizzuto, Giulia, Massari, Alessandro, Perri, Francesco, Annese, Vito, Guidi, L, Fiorino, G, Variola, A, Manetti, N, Fries, W, Rizzuto, G, Bossa, F, Cappello, M, Biancone, L, D'Inca, R, Cantoro, L, Castiglione, F, Principi, M, Annunziata, Ml, Di Girolamo, M, Terpin, Mm, Cortelezzi, Cc, Costa, F, Amato, A, Di Sabatino, A, Saibeni, S, Meucci, G, Petruzzellis, C, Tari, R, Gugliemi, Fw, Armuzzi, A, Danese, S, Geccherle, A, Rogai, F, Ventra, A, Orlando, A, Andriulli, A, Scrivo, B, Troncone, E, Caccaro, R, Kohn, A, Nardone, O, and Annese, V
Subjects: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Adolescent, Settore MED/12 - GASTROENTEROLOGIA, Biosimilar, Crohn's disease, CT-P13, Inflammatory bowel disease, Inflectra, Infliximab, Remsima, Ulcerative colitis, Antibodies, Monoclonal, Female, Follow-Up Studies, Gastrointestinal Agents, Humans, Inflammatory Bowel Diseases, Italy, Prognosis, Prospective Studies, Young Adult, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Monoclonal, medicine, Immunology and Allergy, Prospective cohort study, business.industry, ulcerative colitis, inflammatory bowel disease, biosimilar, Settore MED/09 - MEDICINA INTERNA, Gastroenterology, medicine.disease, 030104 developmental biology, Cohort, 030211 gastroenterology & hepatology, Calprotectin, business, Cohort study, medicine.drug
Abstract: BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. CONCLUSIONS In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.
Published: 2018

27. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy

Author: Angelo Andriulli, Tommaso Stroffolini, Evangelista Sagnelli, Giovanni Battista Gaeta, Bruno Cacopardo, Sergio Babudieri, Caterina Sagnelli, Piero Luigi Almasio, Nicola Coppola, Sagnelli, Evangelista, Stroffolini, Tommaso, Sagnelli, Caterina, Cacopardo, Bruno, Andriulli, Angelo, Babudieri, Sergio, Coppola, Nicola, Gaeta, Giovanni B., and Almasio P.L.
Subjects: Male, Cirrhosis, Time Factors, Administration, Oral, Hepacivirus, medicine.disease_cause, Chronic liver disease, Severity of Illness Index, 0302 clinical medicine, Risk Factors, Odds Ratio, Prevalence, Medicine, 030212 general & internal medicine, Prospective Studies, Multivariate Analysi, Gastroenterology, Health Survey, Middle Aged, Viral Load, Italy, RNA, Viral, 030211 gastroenterology & hepatology, Female, Human, Adult, medicine.medical_specialty, Logistic Model, Time Factor, Genotype, Hepatitis C virus, Antiviral Agents, Virus, 03 medical and health sciences, Age Distribution, Internal medicine, chronic hepatitis C, Humans, Sex Distribution, Protective Factor, Aged, Antiviral Agent, Cross-Sectional Studie, Hepatitis B virus, Hepaciviru, Chi-Square Distribution, Hepatology, business.industry, Risk Factor, chronic liver disease, Biomarker, Odds ratio, Hepatitis C Antibodies, Hepatitis C, Chronic, Protective Factors, medicine.disease, Health Surveys, Confidence interval, direct-acting antiviral therapy, Prospective Studie, hepatitis infection, Cross-Sectional Studies, Logistic Models, Multivariate Analysis, Etiology, Hepatitis C Antibodie, business, Biomarkers
Abstract: Background In 2017, oral direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection became available free of charge for all HCV-RNA-positive patients, irrespective of their fibrosis stage. Aim The aim of this study was to evaluate the characteristics of HCV-related chronic liver disease (CLD) in Italy just before the introduction of DAA therapy. Patients and methods Patients with CLD were enrolled in two national surveys conducted in 2001 and in 2014. The two surveys prospectively enrolled patients aged older than 18 years referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results Out of the 12 564 patients enrolled, 8447 (67.3%) were anti-HCV-positive, with a decreasing trend from 69.0% in 2001 to 60.4% in 2014. During this period, an increasing trend over time was observed in the mean age of patients (55.6 vs. 59.1 years; P
Published: 2018

28. T06.02.10 YOUNG ONSET COLORECTAL CANCER: IDENTIFICATION OF A NEW DELETERIOUS VARIANT IN ATM

Author: Angelo Andriulli, Giuseppe Biscaglia, Anna Panza, F. Abbruzzi, Giuseppina Martino, and Orazio Palmieri
Subjects: Oncology, medicine.medical_specialty, Hepatology, business.industry, Colorectal cancer, Internal medicine, Young onset, Gastroenterology, medicine, Identification (biology), business, medicine.disease
Published: 2020

29. OC.10.1 THE USE OF PRE-ENDOSCOPIC INTRAVENOUS PROTON PUMP INHIBITORS (PPIS) HAD NO IMPACT ON CLINICAL OUTCOMES IN ACUTE UPPER GASTROINTESTINAL BLEEDING: A PROSPECTIVE MULTICENTER ITALIAN COHORT STUDY

Author: A. Andriulli, R. Pumpo, G. Spinzi, L. Amitrano, G. Baldassarre, Marco Soncini, Riccardo Marmo, M. De Matthaeis, C. Londoni, L. Furio, L. Ferraris, S. Metrangolo, A. Balzano, L.G. Cavallaro, G. D'Amico, A. Lauri, E. Buscarini, V. Boarino, A. Merighi, B. Germanà, D. Spotti, P. Di Giorgio, L. Orsini, G. Imperiali, R. Lamanda, F. De Nigris, Alessandra Dell'Era, S. Bargiggia, D. Conte, F. Cipolletta, A. Nucci, P. Cesaro, A. Bizzotto, F.R. De Filippo, A. Anderloni, Maria Elena Riccioni, C. Marmo, A. Repici, A. Paterlini, A. Chirico, G. Napolitano, S. Mangiafico, C. De Fanis, O. Triossi, G. Rotondano, Annalisa Tortora, Guido Costamagna, F. Esposito, P. Borgheresi, L.M. Montalbano, E. Di Giulio, M. Franceschi, Cristina Bucci, R. Bennato, M. Manno, L. Purita, L. Cipolletta, R. Conigliaro, R.M. Zagari, R. De Franchis, A. Zambelli, F. Bazzoli, A. Russo, M.A. Bianco, G. Bresci, M. Parravicini, F. Parente, and S. Segato
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, Acute upper gastrointestinal bleeding, business, Cohort study
Published: 2020

30. T01.01.7 THE USE OF A SPECIALIZED BLEEDING-MANAGEMENT TEAM HAD NO IMPACT ON MORTALITY FOR ACUTE UPPER GASTROINTESTINAL BLEEDING: AN ITALIAN PROSPECTIVE MULTICENTER COHORT STUDY

Author: L. Purita, S. Segato, L. Ferraris, G. D'Amico, E. Buscarini, G. Imperiali, L. Orsini, F. Parente, Maria Elena Riccioni, P. Borgheresi, L.M. Montalbano, Annalisa Tortora, Guido Costamagna, G. Spinzi, M. Franceschi, S. Mangiafico, A. Balzano, A. Lauri, C. De Fanis, A. Russo, M.A. Bianco, G. Bresci, R.M. Zagari, C. Londoni, A. Andriulli, R. De Franchis, A. Zambelli, F. Bazzoli, L.G. Cavallaro, S. Bargiggia, R. Bennato, D. Conte, M. Manno, F. Esposito, A. Chirico, S. Metrangolo, A. Anderloni, V. Boarino, D. Spotti, O. Triossi, B. Germanà, R. Lamanda, G. Baldassarre, P. Cesaro, M. Parravicini, Cristina Bucci, L. Cipolletta, R. Conigliaro, F. Cipolletta, Alessandra Dell'Era, A. Repici, A. Paterlini, F. De Nigris, G. Napolitano, R. Pumpo, A. Nucci, Marco Soncini, A. Merighi, Riccardo Marmo, A. Bizzotto, F.R. De Filippo, C. Marmo, G. Rotondano, L. Furio, E. Di Giulio, L. Amitrano, M. De Matthaeis, and P. Di Giorgio
Subjects: medicine.medical_specialty, Hepatology, business.industry, Emergency medicine, Gastroenterology, Medicine, Acute upper gastrointestinal bleeding, business, Cohort study
Published: 2020

31. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy: Erratum

Author: Sergio Babudieri, Caterina Sagnelli, Angelo Andriulli, Giovanni Battista Gaeta, Tommaso Stroffolini, Alberto Cacopardo, Nicola Coppola, Bruno Cacopardo, Evangelista Sagnelli, and Pier Luigi Almasio
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatitis C virus, Gastroenterology, medicine, Antiviral therapy, business, medicine.disease_cause, Direct acting
Published: 2019

32. Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry

Author: Cremon, C, Carabotti, M, Cuomo, R, Pace, F, Andreozzi, P, Barbaro, Mr, Annibale, B, Barbara, G, on behalf of the REMAD Group, Andrealli, A, Andriulli, A, Ardizzone, S, Astegiano, M, Bachetti, F, Bartolozzi, S, Bargiggia, S, Bassotti, G, Bianco, Ma, Binda, Ga, Biscaglia, G, Bosani, M, Bottiglieri, Me, Cargiolli, M, Ciacci, C, Colecchia, A, Dell’Era, A, De Matthaeis, M, Dinelli, M, Festa, V, Festi, D, Galliani, E, Garribba, A, Germana’, B, Grassini, M, Guido, E, Iafrate, F, Iovino, P, Iuliano, D, Laghi, A, Latella, G, Lorusso, M, Manes, G, Marchi, S, Mauro, B, Maurano, A, Nascimbeni, R, Neri, M, Occhipinti, P, Parravicini, M, Pennazio, M, Peralta, S, Portincasa, P, Radaelli, F, Rossi, M, Salerno, R, Savarino, V, Segato, S, Severi, C, Scaccianoce, G, Usai, P, Valle, V, Virgilio, C, Viscido, A, Cremon C., Carabotti M., Cuomo R., Pace F., Andreozzi P., Barbaro M.R., Annibale B., and Barbara G.
Subjects: Male, medicine.medical_specialty, Treatment outcome, Anti-Inflammatory Agents, symptomatic uncomplicated, symptomatic uncomplicated diverticular disease, registry, previous diverticuliti, Nationwide survey, 03 medical and health sciences, 0302 clinical medicine, pharmacological treatment, Risk Factors, medicine, Diverticulosis, management, pharmacological treatments, previous diverticulitis, registry, symptomatic uncomplicated, Effective treatment, Humans, Registries, Intensive care medicine, Aged, Diverticulosis, Diverticular Diseases, management, pharmacological treatments, previous diverticulitis, business.industry, Diverticulosi, digestive, oral, and skin physiology, Gastroenterology, Original Articles, Middle Aged, medicine.disease, digestive system diseases, Treatment Outcome, Oncology, Italy, 030220 oncology & carcinogenesis, Health Care Surveys, Female, Diverticular disease, 030211 gastroenterology & hepatology, business
Abstract: Background: Although diverticular disease is a common condition, its effective treatment is challenging in clinical practice. Objective: The objective of this article is to assess pharmacological management in different clinical settings of diverticular disease and factors associated with treatment using the Italian registry Registro Malattia Diverticolare (REMAD). Methods: At study enrolment, patients were categorised into subgroups: diverticulosis, symptomatic uncomplicated diverticular disease and previous diverticulitis. We registered demographic, clinical and lifestyle factors, quality of life and the use of treatments for diverticular disease in the last year. Logistic regression analysis assessed the association between clinical factors and treatment consumption. Results: A total of 500 of the 1206 individuals included had had at least one treatment for diverticular disease in the last year: 23.6% (166/702) of patients with diverticulosis, 55.9% (165/295) of patients with symptomatic diverticular disease, and 80.9% (169/209) of patients with previous diverticulitis (p < 0.001). In multivariate analysis, the following factors were significantly associated with treatment use: female gender, family history of colonic diverticula, organic digestive comorbidity and impaired physical quality of life components. Conclusion: Individuals with diverticular disease take medications based on the different clinical settings of disease. We identified different features associated with treatment use in the distinct clinical entities of diverticular disease. ClinicalTrial.gov Identifier: NCT03325829.
Published: 2019

33. Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis

Author: Basili, Stefania, Carnevale, Roberto, Nocella, Cristina, Bartimoccia, Simona, Raparelli, Valeria, Talerico, Giovanni, Stefanini, Lucia, Romiti, Giulio F, Perticone, Francesco, Corazza, Gino R, Piscaglia, Fabio, Pietrangelo, Antonello, Violi, Francesco, and PRO-LIVER collaborators, : Ainora Maria Elena, Andreozzi, Paola, Andriulli, Angelo, Angelico, Francesco, Angelico, Mario, Figliomeni, Antonio, Anzaldi, Massimiliano, Arena, Umberto, Averna, Maurizio, Barone, Milena, Bazzini, Cristina, Bergamaschi, Gaetano, Bertoni, Michele, Bianchi Giovanni Battista, Bianchi Paola Ilaria, Boari, Benedetta, Bombonato, Giancarlo, Bracco, Christian, Brocco, Silvia, Buonauro, Agostino, Buttà, Carmelo, Buzzetti, Elena, Cacciola, Irene, Calabria, Stefano, Cangemi, Roberto, Capeci, William, Caradio, Federica, Carderi, Isabella, Carleo, Pietro, Caroleo, Benedetto, Carrabba Maria Domenica, Castorani, Luigi, Cavallo, Maurizio, Cecchetto, Lara, Cesaro, Flavio, Cicco, Sebastiano, Cimini, Claudia, Colombo Barbara Maria, Corradini, Elena, Corrao, Salvatore, Costantino, Giorgio, Costanzo, Filippo, Croce, Giuseppe, Cuoghi, Chiara, Curigliano, Valentina, D’Alitto, Felicia, D’Amico, Gennaro, De Franchis Roberto, De Giorgi Alfredo, De Vuono Stefano, Debernardi Venon Wilma, Del Ben Maria, Del Corso Lisette, Delitala, Giuseppe, Denegri, Andrea, Di Cesare Valentina, Di Giosia Paolo, Di Michele Dario, Di Minno Giovanni, Donnarumma, Emilia, Drenaggi, Davide, Durante-Mangoni, Emanuele, Falsetti, Lorenzo, Farcomeni, Alessio, Farinaro, Vincenza, Fasolato, Silvano, Ferrari, Giovanni, Fierro, Tiziana, Forgione, Alessandra, Frugiuele, Pierluigi, Galati, Giovanni, Gallo, Paolo, Garcovich, Matteo, Gargano, Ruggiero, Gasbarrini, Antonio, Gatta, Angelo, Giammanco, Antonina, Giannelli, Gianluigi, Giorgini, Paolo, Gobbi, Paolo, Granito, Alessandro, Grassi, Davide, Greco, Antonio, Grembiale, Alessandro, Gresele, Paolo, Hijazi, Daniel, Iacobellis, Angelo, Iamele, Luigi, Invernizzi, Pietro, Ippolito, Antonio, Laffi, Giacomo, Licata, Anna, Liguori Maria Livia, Lorusso, Giusi, Maimone, Sergio, Manfredini, Roberto, Marcacci, Matteo, Marchese, Alessandra, Marinelli, Sara, Marra Alberto Maria, Martino Giuseppe Pio, Masala, Maristella, Masotti, Michela, Merla, Antonio, Miceli, Giuseppe, Montebianco Abenavoli Ludovico, Morana, Ignazio, Morelli, Olivia, Murgia, Giuseppe, Naccarato, Paola, Neri, Sergio, Niro, Grazia, Nobili, Lorenzo, Padula, Donatella, Palasciano, Giuseppe, Palmieri Vincenzo Ostilio, Pastori, Daniele, Pattoneri, Paolo, Perego, Francesca, Perticone, Maria, Pesce, Paola, Petramala, Luigi, Pettinari, Irene, Piano, Salvatore, Picardi, Antonio, Pignataro Francesca Serena, Pignataro, Pietro, Pignatelli, Pasquale, Pinna, Miriam, Pinto, Antonio, Pinto, Daniela, Polimeni, Licia, Pretti, Vincenzo, Privitera, Graziella, Proietti, Marco, Pucci, Giacomo, Purrello, Francesco, Ragone, Enrico, Raimondo, Giovanni, Restuccia, Tea, Riccardi, Laura, Rizzetto, Mario, Rodríguez-Castro Kryssia Isabel, Romanelli Roberto Giulio, Ruscio, Eleonora, Sacerdoti, David, Salinaro, Francesco, Salvi, Aldo, Salzano, Andrea, Santangelo, Giuseppe, Santarossa, Claudia, Santilli, Francesca, Santovito, Daniela, Scarpini, Francesca, Schiavone, Cosima, Scicali, Roberto, Senzolo, Marco, Serra, Carla, Serviddio, Gaetano, Sirico, Domenico, Soresi, Maurizio, Sperduti, Nicolò, Staffolani, Silvia, Staltari, Orietta, Stasi, Cristina, Suppressa, Patrizia, Svegliati Baroni Gianluca, Talia, Michela, Tana, Claudio, Tassone Eliezer Joseph, Todisco, Tommaso, Toriello, Filippo, Torres, Daniele, Traversa, Matteo, Tripepi, Giovanni, Tufano, Antonella, Tuttolomondo, Antonino, Varvara, Doriana, Vazzana, Natale, Vecchio Claudia Rita, Vendemiale, Gianluigi, Ventura, Paolo, Vespasiani-Gentilucci, Umberto, Vettore, Elia, Vidili, Gianpaolo, Villani, Rosanna, Vincenzo, Ronca, Visioli, Giacomo, Vitale, Francesco, Zocco Maria, Assunta., and Stefania Basili, Roberto Carnevale, Cristina Nocella, Simona Bartimoccia, Valeria Raparelli, Giovanni Talerico, Lucia Stefanini, Giulio F. Romiti, Francesco Perticone, Gino R. Corazza, Fabio Piscaglia, Antonello Pietrangelo, Francesco Violi, PRO-LIVER Collaborators, Alessandro Granito
Subjects: medicine.medical_specialty, Cirrhosis, Isoprostane, Urinary system, serum albumin, Serum albumin, Gastroenterology, NO, chemistry.chemical_compound, Internal medicine, Medicine, Platelet, portal vein thrombosis, Platelet activation, Portal vein thrombosis, Albumin, risk, protein, albumin, risk, Hepatology, biology, business.industry, cirrhosis, Albumin, Original Articles, medicine.disease, Portal vein thrombosis, chemistry, biology.protein, Original Article, protein, albumin, portal vein thrombosis, cirrhosis, business
Abstract: We analyzed whether serum albumin is independently associated with portal vein thrombosis (PVT) in liver cirrhosis (LC) and if a biologic plausibility exists. This study was divided into three parts. In part 1 (retrospective analysis), 753 consecutive patients with LC with ultrasound‐detected PVT were retrospectively analyzed. In part 2, 112 patients with LC and 56 matched controls were entered in the cross‐sectional study. In part 3, 5 patients with cirrhosis were entered in the in vivo study and 4 healthy subjects (HSs) were entered in the in vitro study to explore if albumin may affect platelet activation by modulating oxidative stress. In the 753 patients with LC, the prevalence of PVT was 16.7%; logistic analysis showed that only age (odds ratio [OR], 1.024; P = 0.012) and serum albumin (OR, −0.422; P = 0.0001) significantly predicted patients with PVT. Analyzing the 112 patients with LC and controls, soluble clusters of differentiation (CD)40‐ligand (P = 0.0238), soluble Nox2‐derived peptide (sNox2‐dp; P < 0.0001), and urinary excretion of isoprostanes (P = 0.0078) were higher in patients with LC. In LC, albumin was correlated with sCD40L (Spearman’s rank correlation coefficient [rs], −0.33; P < 0.001), sNox2‐dp (rs, −0.57; P < 0.0001), and urinary excretion of isoprostanes (rs, −0.48; P < 0.0001) levels. The in vivo study showed a progressive decrease in platelet aggregation, sNox2‐dp, and urinary 8‐iso prostaglandin F2α‐III formation 2 hours and 3 days after albumin infusion. Finally, platelet aggregation, sNox2‐dp, and isoprostane formation significantly decreased in platelets from HSs incubated with scalar concentrations of albumin. Conclusion: Low serum albumin in LC is associated with PVT, suggesting that albumin could be a modulator of the hemostatic system through interference with mechanisms regulating platelet activation.
Published: 2019

34. Correction to: Accuracy and inter-observer agreement of the nice and kudo classifications of superficial colonic lesions: a comparative study

Author: Antonio Merla, Paola Parente, Mariano Piazzolla, Francesco Cocomazzi, Rosa Paolillo, Sonia Carparelli, Alessia Mileti, Massimiliano Copetti, M. Gentile, Paolo Graziano, Rossella Cubisino, Angelo Andriulli, Francesco Perri, Fabrizio Bossa, Antonella Marra, Alfredo Di Leo, and Antonio Massimo Ippolito
Subjects: medicine.medical_specialty, business.industry, Inter observer agreement, Published Erratum, Gastroenterology, MEDLINE, Nice, Hepatology, Internal medicine, Medicine, Radiology, business, computer, computer.programming_language
Published: 2021

35. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Author: Maria Teresa Sartori, Agostino Colli, Francesco Violi, Armando Tripodi, Alessandro Vitale, Pier Mannuccio Mannucci, Paolo Caraceni, Paolo Angeli, Vincenzo La Mura, Cristina Lucidi, Laura Napoleone, Paolo Feltracco, Elvira Grandone, Fabio Piscaglia, Daniele Prati, Marco Marzioni, Massimo Zuin, Angelo Andriulli, Paolo Rebulla, Dario Ribero, Gianluca Svegliati Baroni, Anna Licata, Marco Marietta, Oliviero Riggio, Antonella Tufano, Erica Villa, Marco Senzolo, Filippo Schepis, Antonella Scalera, Sergio Maimone, Massimo Siciliano, Lesley De Pietri, Domenico Ferro, Giovanni Di Minno, Vincenza Calvaruso, Marco Falcone, Edoardo G. Giannini, David Sacerdoti, Valeria Raparelli, Stefania Basili, Filomena Morisco, Salvatore Piano, Carlo Merkel, Massimo Primignani, Andriulli, Angelo, Tripodi, Armando, Angeli, Paolo, Senzolo, Marco, Primignani, Massimo, Giannini, Edoardo G., Riggio, Oliviero, Colli, Agostino, Prati, Daniele, Sacerdoti, David, Merkel, Carlo, Basili, Stefania, Ferro, Domenico, Villa, Erica, Di Minno, Giovanni, Caraceni, Paolo, Marzioni, Marco, Mannucci, Pier Mannuccio, Violi, Francesco, Piscaglia, Fabio, Calvaruso, Vincenza, De Pietri, Lesley, Falcone, Marco, Feltracco, Paolo, Grandone, Elvira, La Mura, Vincenzo, Licata, Anna, Lucidi, Cristina, Maimone, Sergio, Marietta, Marco, Morisco, Filomena, Napoleone, Laura, Piano, Salvatore, Raparelli, Valeria, Rebulla, Paolo, Ribero, Dario, Sartori, Maria Teresa, Scalera, Antonella, Schepis, Filippo, Sicilianom, Massimo, Baroni, Gianluca Svegliati, Tufano, Antonella, Vitale, Alessandro, Zuin, Massimo, DI MINNO, Giovanni, Angelo, A, Armando, T, Paolo, A, Marco, S, Massimo, P, Edoardo G., G, Oliviero, R, Agostino, C, Daniele, P, David, S, Carlo, M, Stefania, B, Domenico, F, Erica, V, Giovanni Di, M, Paolo, C, Marco, M, Pier Mannuccio, M, Francesco, V, Fagiuoli, S, Andriulli, A, Tripodi, A, Angeli, P, Senzolo, M, Primignani, M, Giannini, EG, Riggio, O, Colli, A, Prati, D, Sacerdoti, D, Merkel, C, Basili, S, Ferro, D, Villa, E, Di Minno, G, Caraceni, P, Marzioni, M, Mannucci, PM, Violi, F, Piscaglia, F, Calvaruso, V, De Pietri, L, Falcone, M, Feltracco, P, Grandone, E, La Mura, V, Licata, A, Lucidi, C, Maimone, S, Marietta, M, Morisco, F, Napoleone, L, Piano, S, Raparelli, V, Rebulla, P, Ribero, D, Sartori, M, Scalera, A, Schepis, F, Siciliano, M, Baroni, G.S, Tufano, A, Vitale, A, and Zuin, M
Subjects: Liver Cirrhosis, Cirrhosis, Bleeding, Hemostasis, Thrombosis, Hepatology, Gastroenterology, Settore MED/09 - Medicina Interna, Anticoagulants, Coagulants, Drug Monitoring, Esophageal and Gastric Varices, Gastrointestinal Hemorrhage, Humans, Postoperative Hemorrhage, Blood Coagulation Tests, 0302 clinical medicine, Esophageal and Gastric Varice, Blood coagulation test, Consensus conference, Optimal management, Coagulant, 030220 oncology & carcinogenesis, Thrombosi, 030211 gastroenterology & hepatology, Human, medicine.medical_specialty, Liver Cirrhosi, NO, 03 medical and health sciences, Internal medicine, medicine, In patient, Intensive care medicine, Cirrhosi, business.industry, Anticoagulant, Hemostasi, Blood Coagulation Test, medicine.disease, Surgery, business
Abstract: Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent jury. The statements presented here highlight strengths and weaknesses of current laboratory tests to assess bleeding and thrombotic risk in cirrhotic patients, the pathophysiology of hemostatic perturbations in this condition, and outline the optimal management of bleeding and thrombosis in patients with liver cirrhosis.
Published: 2016

36. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response

Author: A. Smedile, Grazia Anna Niro, Pietro Andreone, R. Fontana, Mario Rizzetto, H. Wedemeyer, Maria Rosa Valvano, A. Iacobellis, Nicola Coppola, Fabrizia Pittaluga, G. Lotti, Antonella Olivero, Massimo Fasano, Alessia Ciancio, Angelo Andriulli, Aldo Marrone, Kalliopi Zachou, Niro, Ga, Smedile, A, Fontana, R, Olivero, A, Ciancio, A, Valvano, Mr, Pittaluga, F, Coppola, Nicola, Wedemeyer, H, Zachou, K, Marrone, Aldo, Fasano, M, Lotti, G, Andreone, P, Iacobellis, A, Andriulli, A, Rizzetto, M., Niro, G.A, Smedile, A., Fontana, R., Olivero, A., Ciancio, A., Valvano, M.R., Pittaluga, F., Coppola, N., Wedemeyer, H., Zachou, K., Marrone, A., Fasano, M., Lotti, G., Andreone, P., Iacobellis, A., and Andriulli, A.
Subjects: 0301 basic medicine, Male, HBsAg, Hepatitis D, Chronic, HDV-RNA, medicine.medical_treatment, viruses, Gastroenterology, peghilated Interferon, 0302 clinical medicine, Pegylated interferon, Interferon, HBsAg kinetic, Pharmacology (medical), treatment, virus diseases, Middle Aged, Prognosis, Hepatitis D, Treatment Outcome, Hepatitis delta, RNA, Viral, 030211 gastroenterology & hepatology, Female, Immunotherapy, Hepatitis Delta Virus, medicine.drug, Adult, medicine.medical_specialty, Viremia, 03 medical and health sciences, Antigen, Chronic hepatitis, Internal medicine, HDV, medicine, Humans, Hepatitis delta, HDV, treatment, HBsAg kinetic, peghilated Interferon, HDV-RNA, Hepatitis B Surface Antigens, Hepatology, business.industry, biochemical phenomena, metabolism, and nutrition, medicine.disease, Kinetics, 030104 developmental biology, Immunology, Interferons, business
Abstract: Summary Background Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point is disputed. Aim To assess the role of serum hepatitis B surface antigen (HBsAg) in the clearance of HDV-RNA in pegylated interferon (Peg-IFN)-treated chronic hepatitis D (CHD). Methods Sixty-two patients with CHD, treated with Peg-IFN, were considered. The patients belonged to three groups: 14 patients cleared the HBsAg and HDV-RNA (responders, R), 12 cleared the HDV-RNA remaining positive for HBsAg (partial responders, PR) and 36 cleared neither the HBsAg nor the HDV-RNA (nonresponders, NR). Results In responders, at baseline the median value (mv) of HBsAg and HDV-RNA was 1187 and 188 663 IU/mL. By month 6 of therapy, HBsAg declined to less than 1000 IU/mL and HDV-RNA was undetectable in 12 patients. In NR, the pre-therapy median value of HBsAg and HDV viremia was 6577 and 676 319 IU/mL. There was no significant reduction of antigen at month 6; after a decline, HDV-RNA rebounded to baseline levels. In PR, the median value of baseline HBsAg was 7031 IU/mL; it declined at month 6 in the majority. HDV-RNA progressively declined from an initial median value of 171 405 IU/mL. HBsAg
Published: 2016

37. Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

Author: Tommaso Stroffolini, Evangelista Sagnelli, Giovanni Battista Gaeta, Caterina Sagnelli, Angelo Andriulli, Giuseppina Brancaccio, Mario Pirisi, Guido Colloredo, Filomena Morisco, Caterina Furlan, Piero Luigi Almasio, Sergio Babudieri, Bruno Cacopardo, Nicola Coppola, Massimo De Luca, Anna Licata, Mariantonietta Pisaturo, Floriano Rosina, Maurizio Russello, Teresa Santantonio, Antonina Smedile, Stroffolini, T., Sagnelli, E., Gaeta, G., Sagnelli, C., Andriulli, A., Brancaccio, G., Pirisi, M., Colloredo, G., Morisco, F., Furlan, C., Almasio, P., Babudieri, S., Cacopardo, B., Coppola, N., De Luca, M., Licata, A., Pisaturo, M., Rosina, F., Russello, M., Santantonio, T., Smedile, A., Stroffolini, Tommaso, Sagnelli, Evangelista, Gaeta, Giovanni Battista, Sagnelli, Caterina, Andriulli, Angelo, Brancaccio, Giuseppina, Pirisi, Mario, Colloredo, Guido, Morisco, Filomena, Furlan, Caterina, Almasio, Piero Luigi, Babudieri, S, Cacopardo, B, Coppola, N, De Luca, M, Licata, A, Pisaturo, M, Rosina, F, Russello, M, and Santantonio, T
Subjects: Male, Cirrhosis, Settore MED/09 - Medicina Interna, Alcohol abuse, HBV, HCV, Liver cirrhosis, Liver cirrhosis epidemiology, Internal Medicine, medicine.disease_cause, Gastroenterology, 0302 clinical medicine, Risk Factors, Epidemiology, 030212 general & internal medicine, Liver Neoplasms, virus diseases, Middle Aged, Hepatitis B, Hepatitis C, Alcoholism, Italy, Liver Neoplasm, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Aged, Carcinoma, Hepatocellular, Cross-Sectional Studies, Female, Humans, Liver Cirrhosis, Human, medicine.medical_specialty, Hepatitis C virus, Liver Cirrhosi, 03 medical and health sciences, Internal medicine, medicine, Decompensation, Hepatitis B virus, Cross-Sectional Studie, business.industry, Risk Factor, Carcinoma, Hepatocellular, medicine.disease, Etiology, business
Abstract: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child A cirrhosis and 17.9% superimposed hepatocellular carcinoma. HCV infection, alone or in combination with other aetiologic agents, was responsible of 58.6% of cases, HBV aetiology accounted for the 17.6% and alcohol abuse for the 16.0%. Compared with virus-related cirrhotic patients, those alcohol-related more frequently showed decompensation (p=0.02). CONCLUSIONS: Compared to previous surveys performed in 1992 and in 2001, we observe a statistically significant (p
Published: 2016

38. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C

Author: Daniele Di Paolo, Vito Di Marco, C. Gavrila, Giovanni Raimondo, Pietro Gatti, Michele Milella, Giovanna D'Andrea, Antonio Craxì, Filomena Morisco, Michele Barone, Martina Felder, Alessio Aghemo, Giuseppe Mazzella, Giovanna Fattovich, Mario Angelico, Teresa Santantonio, Giuseppina Brancaccio, Antonina Smedile, Eleonora Grassi, Giovanni Squadrito, Antonio Massimo Ippolito, Alessandra Nardi, Nicola Andriulli, Angelo Andriulli, Raffaele Cozzolongo, Maria Rosa Valvano, Vincenza Calvaruso, Massimo Fasano, Paolo Tundo, Andriulli, Angelo, Nardi, Alessandra, Di Marco, Vito, Ippolito, Antonio Massimo, Gavrila, Caiu, Aghemo, Alessio, Di Paolo, Daniele, Squadrito, Giovanni, Grassi, Eleonora, Calvaruso, Vincenza, Valvano, Maria Rosa, Brancaccio, Giuseppina, Craxi, Antonio, Angelico, Mario, Raimondo, Giovanni, Milella, Michele, Morisco, Filomena, Fattovich, Giovanna, Felder, Martina, Smedile, Antonina, Fasano, Massimo, Santantonio, Teresa, Gatti, Pietro, Nicolaandriulli, Null, Tundo, Paolo, Barone, Michele, Cozzolongo, Raffaele, Giovanna D'andrea, Null, Mazzella, Giuseppe, Giovanna D'Andrea, Null, Andriulli, A, Nardi, A, Di Marco, V, Ippolito, Am, Gavrila, C, Aghemo, A, Di Paolo, D, Squadrito, G, Grassi, E, Calvaruso, V, Valvano, Mr, Brancaccio, G, Craxi, A, Angelico, M, Collaborator, S., and Collaborators
Subjects: Oncology, Male, Hepacivirus, Predictive Value of Test, chronic hepatitis C, prediction model of response, peginterferon plus ribavirin dual therapy, Polyethylene Glycol, Polyethylene Glycols, chemistry.chemical_compound, Genotype, Viral, Chronic, Rapid virological response, Drug Carrier, Chronic hepatitis, Settore MED/12 - Gastroenterologia, Drug Carriers, biology, Gastroenterology, Recombinant Protein, Middle Aged, Viral Load, Prognosis, Hepatitis C, Recombinant Proteins, HCV infection, Treatment Outcome, Predictive value of tests, Combination, RNA, Viral, Drug Therapy, Combination, Female, Peg-interferon and ribavirin treatment, Predictors of sustained virological response, rapid virological response, Adult, Antiviral Agents, Hepatitis C, Chronic, Humans, Interferon-alpha, Predictive Value of Tests, Real-Time Polymerase Chain Reaction, Ribavirin, Hepatology, Viral load, Human, medicine.medical_specialty, Prognosi, Alpha interferon, Drug Therapy, Internal medicine, Predictors of sustained virological response, Linear regression, medicine, Antiviral Agent, Predictors of sustained virological response, Rapid virological response, Hepaciviru, business.industry, biology.organism_classification, chemistry, Immunology, Chronic hepatiti, RNA, business
Abstract: none 29 no Background: Aim was to select naÃ¯ve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 818 did not, with sustained virological response rates of 80.2% and 25.4%, respectively; interleukin-28B polymorphisms, fibrosis staging, gamma-glutamyl transferase, and viral load predicted sustained virological response. Assuming a
Published: 2014

39. Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

Author: Sagnelli, Evangelista, Stroffolini, Tommaso, Sagnelli, Caterina, Pirisi, Mario, Babudieri, Sergio, Colloredo, Guido, Russello, Maurizio, Coppola, Nicola, Gaeta, Giovanni Battista, Cacopardo, Bruno, De Luca, Massimo, Almasio, Piero Luigi, Andriulli, Angelo, Brancaccio, Giuseppina, Furlan, Caterina, Licata, Anna, Morisco, Filomena, Pisaturo, Mariantonietta, Rosina, Floriano, Rusello, Maurizio, Santantonio, Teresa, Smedile, Antonina, Sagnelli, Evangelista, Stroffolini, Tommaso, Sagnelli, Caterina, Pirisi, Mario, Babudieri, Sergio, Colloredo, Guido, Russello, Maurizio, Coppola, Nicola, Gaeta, Giovanni Battista, Cacopardo, Bruno, De Luca, Massimo, Almasio, Piero Luigi, Andriulli, Angelo, Brancaccio, Giuseppina, Furlan, Caterina, Licata, Anna, Morisco, Filomena, Pisaturo, Mariantonietta, Rosina, Floriano, Rusello, Maurizio, Santantonio, Teresa, and Smedile, Antonina
Subjects: Alcoholic liver disease, Pathology, Cirrhosis, liver diseases, Hepatocellular carcinoma, Prevalence, Chronic liver disease, Gastroenterology, 0302 clinical medicine, cohort studies, Epidemiology, middle aged, 030212 general & internal medicine, humans, Chronic liver diseases, HBV infection, Chronic hepatitis, adult, General Medicine, Hepatitis C, Hepatitis B, HCV infection, aged, Infectious Diseases, Italy, young adult, 030211 gastroenterology & hepatology, Cohort study, Microbiology (medical), medicine.medical_specialty, prevalence, 03 medical and health sciences, Internal medicine, medicine, Liver Diseases, Alcoholic, Alcoholic liver diseases, business.industry, medicine.disease, prospective studies, sex factors, Chronic hepatiti, hepatitis B, hepatitis C, business, chronic disease, alcoholic liver diseases, chronic hepatitis, chronic liver diseases, hepatocellular carcinoma, liver diseases, alcoholic, alcoholic
Abstract: Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014). Methods: The two surveys prospectively recruited patients aged â¥Â 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely to show HCV infection alone (48.0% vs. 67.9%). A male preponderance was observed in HBV-related cases (1.99) and in alcoholic-related cases (2.3), a preponderance observed both in the 2001 and in 2014 cases. In HCV-related cases, however, females predominated in 2001 (M/F 0.9) and males in 2014 (M/F 1.5).The rate of cirrhosis in alcohol-related etiology was close to 36% in both genders, a finding much higher than that observed for both sexes in HBV and HCV etiologies.Both males and females enrolled in 2014 were older (pÂ
Published: 2017

40. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3

Author: Maria Rosa Valvano, Silvia Camera, Angelo Andriulli, Marta Librandi, R. Granata, Vincenzo Messina, A. Iacobellis, Fabio Conti, Michele Milella, Filomena Morisco, Paolo Tundo, Pietro Gatti, Teresa Santantonio, A. Smedile, Nicola Caporaso, C. Masetti, Antonio Patrizio Termite, Antonio Massimo Ippolito, Morisco, Filomena, Granata, Rocco, Camera, Silvia, Ippolito, Antonio, Milella, Michele, Conti, Fabio, Masetti, Chiara, Smedile, Antonella, Tundo, Paolo, Santantonio, Teresa, Valvano, Maria Rosa, Termite, Antonio, Gatti, Pietro, Messina, Vincenzo, Iacobellis, Angelo, Librandi, Marta, Caporaso, Nicola, and Andriulli, Angelo
Subjects: Ledipasvir, medicine.medical_specialty, Cirrhosis, Sofosbuvir, Hepatitis C virus, medicine.disease_cause, Gastroenterology, meta-analysi, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Genotype, medicine, genotype 3, 030212 general & internal medicine, direct antiviral agent, business.industry, Ribavirin, virus diseases, Original Articles, medicine.disease, digestive system diseases, chemistry, Oncology, Treatment Schedule, Meta-analysis, HCV, 030211 gastroenterology & hepatology, business, medicine.drug, cirrhosi
Abstract: Direct antiviral agents (DAAs) have led to high sustained virological responses (SVR) in hepatitis C virus (HCV) patients. However, genotype 3 patients respond to treatment in a suboptimal way. This study aims to identify which of the several treatment schedules recommended for genotype 3 would constitute the best option.Twenty-four Italian centers were involved in this real-life study of HCV genotype 3 patients treated with DAAs. To expand the number of cases, we conducted a systematic review of the literature on the outcome of genotype 3 patients treated with DAAs.A total of 233 patients with HCV genotype 3 were enrolled. Cirrhotic patients accounted for 83.7%. Overall, the SVR12 rate was achieved by 205 patients (88.0%); the SVR rates were 78.8% after sofosbuvir/ribavirin, 92.5% after sofosbuvir/daclatasvir ± ribavirin, and 100% after sofosbuvir/ledipasvir (seven patients). No difference in rate of SVR was observed in cirrhotic and non-cirrhotic patients (92.2 vs 94.4) using a combination regimen of NS5A and NS5B inhibitors.The systematic review of the literature provided data of 3311 patients: The mean weighted SVR12 rate was 84.4% (CI: 80.4-87.8); the rates varied from 79.0% (CI: 70.9-85.3) with sofosbuvir/ribavirin, to 83.7% (CI: 66.2-93.1) with sofosbuvir/ledispavir, and to 88.2% (CI: 83.3-91.7) with sofosbuvir/daclatasvir.Our results reinforce the concept that patients with HCV genotype 3 should no longer be considered difficult-to-treat individuals. The optimal therapeutic regimen for these patients appears to be the combination sofosbuvir/daclatasvir, administered for 12 weeks without the use of RBV in non-cirrhotic patients. In cirrhotics the meta-analytic approach suggests extending therapy to 24 weeks.
Published: 2017

41. Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretationâAuthors' reply

Author: Michele Pier Luca Guarino, Angelo Andriulli, Filomena Morisco, Andriulli, A., Guarino, M., and Morisco, F.
Subjects: Liver Cirrhosis, Pediatrics, medicine.medical_specialty, Pathology, Cirrhosis, Liver Cirrhosi, MEDLINE, Antiviral Agents, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Ribavirin, Medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Child, Antiviral Agent, Hepatology, business.industry, Interferon free, Interpretation (philosophy), Gastroenterology, Hepatitis C, Hepatitis C, Chronic, medicine.disease, chemistry, Interferon, 030211 gastroenterology & hepatology, Interferons, business, Human
Published: 2017

42. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

Author: Fiorino, Gionata, Manetti, Natalia, Armuzzi, Alessandro, Orlando, Ambrogio, Variola, Angela, Bonovas, Stefanos, Bossa, Fabrizio, Maconi, Giovanni, D'Incà, Renata, Lionetti, Paolo, Cantoro, Laura, Fries, Walter, Annunziata, Maria L., Costa, Francesco, Terpin, Maria M., Biancone, Livia, Cortelezzi, Claudio C., Amato, Arnaldo, Ardizzone, Sandro, Danese, Silvio, Guidi, Luisa, Rizzuto, Giulia, Massella, Arianna, Andriulli, Angelo, Massari, Alessandro, Lorenzon, Greta, Ghione, Silvia, Kohn, Anna, Ventra, Agostino, Annese, Vito, Principi, Mariabeatrice, Di Girolamo, Maria, Bertani, Angela, Saettone, Silvia, Tari, Roberto, Petruzzellis, Carlo, Guglielmi, Francesco W., Mazzuoli, Silvia, Cappello, Maria, Viola, Anna, Castiglione, Fabiana, Nardone, Olga, Di Sabatino, Antonio, Saibeni, Simone, Bezzio, Cristina, Caserta, Luigi, Parodi, Maria Caterina, Meucci, Gianmichele, Colli, Agostino, Ronchetti, Anna, Vecchi, Maurizio, Bertani, Lorenzo, Bosani, Matteo A., Tronconi, Edoardo, Imperiali, Gianni, Salerno, Raffaele, Rogai, Francesca, Milani, Stefano, Pugliese, Daniela, Renna, Sara, Geccherle, Andrea, Martino, Giuseppina, Cassinotti, Andrea, Fiorino, G, Manetti, N, Armuzzi, A, Orlando, A, Variola, A, Bonovas, S, Bossa, F, Maconi, G, D'Inca, R, Lionetti, P, Cantoro, L, Fries, W, Annunziata, Ml, Costa, F, Terpin, Mm, Biancone, L, Cortelezzi, Cc, Amato, A, Ardizzone, S, Danese, S, Guidi, L, Rizzuto, G, Massella, A, Andriulli, A, Massari, A, Lorenzon, G, Ghione, S, Kohn, A, Ventra, A, and Annese, V
Subjects: Male, Databases, Factual, Ulcerative, Rate ratio, Inflammatory bowel disease, 0302 clinical medicine, Crohn Disease, Monoclonal, Immunology and Allergy, Prospective Studies, Remsima, Prospective cohort study, Infusions, Intravenous, biosimilar, Crohn's disease, CT-P13, inflammatory bowel disease, Inflectra, Infliximab, ulcerative colitis, Gastroenterology, Adolescent, Adult, Antibodies, Monoclonal, Biosimilar Pharmaceuticals, Colitis, Ulcerative, Female, Gastrointestinal Agents, Humans, Treatment Outcome, Young Adult, Colitis, Ulcerative colitis, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Intravenous, Cohort study, medicine.drug, medicine.medical_specialty, Infusions, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Infliximab, Remsima, Inflectra, biosimilar, CT-P13, Antibodies, 03 medical and health sciences, Databases, Internal medicine, medicine, Adverse effect, Factual, business.industry, Settore MED/09 - MEDICINA INTERNA, medicine.disease, business
Abstract: Background: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease. Methods: A prospective, multicenter, cohort study using a structured database. Results: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 6 14 infusions of infliximab. The mean follow-up was 4.3 6 +/- 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1%), 38 (6.9%) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3%) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9%) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95% CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1%). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive, 97.2%, 85.2%, and 62.2% for pre-exposed, and 94.5%, 90.8%, and 78.9% for switch, respectively (log-rank P = 0.64). Conclusions: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.
Published: 2017

43. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study

Author: Nicola Napoli, Vincenzo Messina, Marianna Zappimbulso, Angelo Andriulli, Gianfranco Lauletta, Giuseppe Bruno, Teresa Santantonio, Raffaele Cozzolongo, Antonio Patrizio Termite, Salvatore Rizzo, C. Masetti, Antonina Smedile, Giuseppina Brancaccio, Antonio Massimo Ippolito, Pietro Gatti, Paolo Tundo, Fabio Conti, Claudia Fabrizio, Giovanni Battista Gaeta, Luca Fontanella, Michele Barone, Antonio Metrangolo, Giuseppe Cuccorese, Michele Milella, Ruggiero Francavilla, Filomena Morisco, Emanuela Ciracì, Vito Carretta, Maria Rosa Valvano, Pietro Andreone, Ippolito, Antonio Massimo, Milella, Michele, Messina, Vincenzo, Conti, Fabio, Cozzolongo, Raffaele, Morisco, Filomena, Brancaccio, Giuseppina, Barone, Michele, Santantonio, Teresa, Masetti, Chiara, Tundo, Paolo, Smedile, Antonina, Carretta, Vito, Gatti, Pietro, Termite, Antonio Patrizio, Valvano, Maria Rosa, Bruno, Giuseppe, Fabrizio, Claudia, Andreone, Pietro, Zappimbulso, Marianna, Gaeta, Giovanni Battista, Napoli, Nicola, Fontanella, Luca, Lauletta, Gianfranco, Cuccorese, Giuseppe, Metrangolo, Antonio, Francavilla, Ruggiero, Ciracì, Emanuela, Rizzo, Salvatore, and Andriulli, Angelo
Subjects: Male, Cirrhosis, Databases, Factual, Sustained Virologic Response, Hepacivirus, Antiviral therapy, Direct-acting antivirals, HCV, Hepatitis C, Liver cirrhosis, Hepatology, Gastroenterology, Direct-acting antiviral, Severity of Illness Index, 0302 clinical medicine, Prospective Studies, Stage (cooking), Prospective cohort study, Multivariate Analysi, biology, Middle Aged, Italy, Liver, 030220 oncology & carcinogenesis, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Human, medicine.medical_specialty, Logistic Model, Liver Cirrhosi, Antiviral Agents, 03 medical and health sciences, Internal medicine, Severity of illness, medicine, Humans, Aged, Antiviral Agent, Hepaciviru, business.industry, medicine.disease, biology.organism_classification, Prospective Studie, Logistic Models, Multivariate Analysis, Varices, business
Abstract: Background Sustained virological response (SVR12) rates at 12 weeks after treatment for HCV-infected patients with decompensated cirrhosis are used when referring to those with moderate functional impairment, while few data are available for those with more severe impairment. The use of the cirrhosis staging system proposed by D’Amico might provide new insights on timing for antiviral therapy. Methods We investigated efficacy (SVR12), safety, and post-treatment variations in clinical and laboratory parameters in 2612 patients with advanced fibrosis (n = 575) or cirrhosis (n = 2037). Cirrhosis was in the compensated phase (without/with varices) or had previously been in the decompensated stage. Different direct-acting antiviral (DAA) regimens were administered in accordance with scientific guidelines. Results The SVR12 rate was 97.6% in patients with advanced fibrosis. For patients with cirrhosis, the rate was 96.5% in stage 1, 95.1% in stage 2, 100% in stage 3, 95.7% in stage 4, and 93.6% in stage 5. These rates were independent of gender, age, HCV genotype, and treatment schedule. Positive changes in biochemical parameters and CPT classes following therapy were evident in compensated and previously decompensated patients. Conclusion Our findings support the use of DAAs in patients with advanced cirrhosis (stages 3–5) who are at greatest risk and have the most to gain from therapy.
Published: 2017

44. Transperineal ultrasonography: First level exam in IBD patients with perianal disease

Author: Francesco Perri, Fulvia Terracciano, Giuseppe Scalisi, Angelo Andriulli, Giuseppe Biscaglia, Daniela Scimeca, Maria Rosa Valvano, Anna Simeone, Michele Mangiacotti, and Fabrizio Bossa
Subjects: Adult, Male, medicine.medical_specialty, Concordance, Perineum, Inflammatory bowel disease, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Transperineal ultrasonography, medicine, Humans, Rectal Fistula, In patient, Prospective Studies, Ultrasonography, Pelvic floor, Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Magnetic resonance imaging, Perianal disease, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Magnetic Resonance Imaging, Abscess, medicine.anatomical_structure, Italy, 030220 oncology & carcinogenesis, Classification methods, Female, 030211 gastroenterology & hepatology, Radiology, business
Abstract: Background A pelvic magnetic resonance imaging (MRI) represents the front-line method for evaluating perianal disease in patients with inflammatory bowel disease (IBD). Recently, transperineal ultrasonography (TPUS) has been proposed as a simple, safe, time-sparing and useful diagnostic technique to assess different pathological conditions of the pelvic floor. Aim The aim of this prospective single centre study was to evaluate the accuracy of TPUS versus MRI for the detection and classification of perineal disease in IBD patients. Methods From November 2013 to November 2014, 28 IBD patients underwent either TPUS or MRI. Fistulae and abscesses were classified according to Parks’ and AGA's classification methods. A concordance was assessed by k statistics. Results Overall, 33 fistulae and 8 abscesses were recognized by TPUS (30 and 7 by MRI, respectively). The agreement between TPUS and MRI was 75% according to Parks’ classification ( k = 0.67) and 86% according to AGA classification ( k = 0.83), while it was 36% ( k = 0.34) for classifying abscesses. Conclusions TPUS proved to be as accurate as MRI for detecting superficial and small abscesses and for classifying perianal disease. Both examinations may be performed at the initial presentation of the patient, but TPUS is a cheaper, time-sparing procedure. The optimal use of TPUS might be in follow-up patients.
Published: 2016

45. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites

Author: Fulvio Mattivi, Angelo Andriulli, Andrea Fontana, Iole Maria Di Gangi, Massimiliano Copetti, Tommaso Mazza, Anna Latiano, Urska Vrhovsek, Antonio Massimo Ippolito, Caterina Fusilli, and Valerio Pazienza
Subjects: 0301 basic medicine, Settore CHIM/01 - CHIMICA ANALITICA, Pathology, pancreatic cancer, Acido palmitico, Gastroenterology, Mass Spectrometry, 0302 clinical medicine, UHPLC, Discriminant Analysis, Early diagnosis, Prognosis, Oncology, 030220 oncology & carcinogenesis, Metabolome, Adenocarcinoma, High dimensionality, Research Paper, metabolomic, medicine.medical_specialty, Spettrometria di massa, Metabolomic, Tumore al pancreas, 03 medical and health sciences, Metabolomics, Palmitic acid, Pancreatic cancer, Internal medicine, medicine, Biomarkers, Tumor, Humans, Receiver operating characteristic, business.industry, Case-control study, Cancer, Metabolomica, medicine.disease, Confidence interval, Pancreatic Neoplasms, Biomarcatori, 030104 developmental biology, ROC Curve, Diagnosi precoce, Case-Control Studies, business, Biomarkers
Abstract: // Iole Maria Di Gangi 1 , Tommaso Mazza 2 , Andrea Fontana 3 , Massimiliano Copetti 3 , Caterina Fusilli 2 , Antonio Ippolito 4 , Fulvio Mattivi 1 , Anna Latiano 4 , Angelo Andriulli 4 , Urska Vrhovsek 1, * , Valerio Pazienza 4, * 1 Department of Food Quality and Nutrition, Research and Innovation Centre, Fondazione Edmund Mach (FEM), San Michele all’Adige, TN, Italy 2 Unit of Bioinformatics, I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, FG, Italy 3 Unit of Biostatistics I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, FG, Italy 4 Gastroenterology Unit, I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, FG, Italy * These authors have contributed equally to this work Correspondence to: Valerio Pazienza, e-mail: pazienza_valerio@yahoo.it Keywords: metabolomic, pancreatic cancer Received: July 27, 2015 Accepted: December 26, 2015 Published: January 01, 2016 ABSTRACT Purpose: pancreatic adenocarcinoma is the fourth leading cause of cancer related deaths due to its aggressive behavior and poor clinical outcome. There is a considerable variability in the frequency of serum tumor markers in cancer’ patients. We performed a metabolomics screening in patients diagnosed with pancreatic cancer. Experimental Design: Two targeted metabolomic assays were conducted on 40 serum samples of patients diagnosed with pancreatic cancer and 40 healthy controls. Multivariate methods and classification trees were performed. Materials and Methods: Sparse partial least squares discriminant analysis (SPLS-DA) was used to reduce the high dimensionality of a pancreatic cancer metabolomic dataset, differentiating between pancreatic cancer (PC) patients and healthy subjects. Using Random Forest analysis palmitic acid, 1,2-dioleoyl-sn-glycero-3-phospho-rac-glycerol, lanosterol, lignoceric acid, 1-monooleoyl-rac-glycerol, cholesterol 5α,6α epoxide, erucic acid and taurolithocholic acid (T-LCA), oleoyl-L-carnitine, oleanolic acid were identified among 206 metabolites as highly discriminating between disease states. Comparison between Receiver Operating Characteristic (ROC) curves for palmitic acid and CA 19-9 showed that the area under the ROC curve (AUC) of palmitic acid (AUC=1.000; 95% confidence interval) is significantly higher than CA 19-9 (AUC=0.963; 95% confidence interval: 0.896-1.000). Conclusion: Mass spectrometry-based metabolomic profiling of sera from pancreatic cancer patients and normal subjects showed significant alterations in the profiles of the metabolome of PC patients as compared to controls. These findings offer an information-rich matrix for discovering novel candidate biomarkers with diagnostic or prognostic potentials.
Published: 2016

46. Correction to: A New Intraepithelial γδ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies

Author: Paolo Graziano, Angelo Andriulli, Markku Mäki, Paola Parente, Juha Taavela, Alina Popp, Claudia Covelli, Carmela Lamacchia, and Jorma Isola
Subjects: T lymphocyte marker, Pathology, medicine.medical_specialty, Paraffin Embedding, Tissue Fixation, Formalin fixed paraffin embedded, Duodenum, Physiology, business.industry, T-Lymphocytes, Gastroenterology, Correction, Antibodies, Monoclonal, Disease classification, Receptors, Antigen, T-Cell, gamma-delta, Immunohistochemistry, Celiac Disease, Formaldehyde, Medicine, business, Biomarkers
Abstract: The histopathologic diagnosis of celiac disease (CD) may be challenging when the duodenal biopsies mucosal injury is limited. Intraepithelial T-lymphocytes (IELs) can be useful to characterize the degree of mucosal inflammation. A small fraction of IELs expresses the γδ T-cell receptor (named γδ-IELs), whose density, determined by flow cytometry or frozen section immunohistochemistry (IHC), is a specific marker for CD.To establish a new IHC assay for γδ-IELs applicable to formalin-fixed paraffin-embedded (FFPE) duodenal biopsies.We analyzed γδ-IELs using IHC in 138 duodenal biopsies using a standard IHC staining protocol with a new monoclonal antibody H-41. IELs were quantitated with digital image analysis.Compared to those in non-celiac controls (n = 51), γδ-IEL density was significantly increased in newly diagnosed celiac disease patients (n = 22, p 0.0001). In ROC-curve analysis, the cutoff of 6.5 γδ-IELs/100 enterocytes distinguished optimally active CD patients from non-celiac controls (sensitivity 96%, specificity 95%). γδ-IEL density in CD patients on a gluten-free diet (n = 53) were also higher than in controls (p 0.0001), but lower than those in newly diagnosed CD (p 0.0001). The diagnostic value of γδ-IELs outperformed that of CD3 + IELs in both patient groups. γδ-IELs were better than CD3 + IELs distinguishing between celiac disease and conditions histologically mimicking celiac disease (n = 12).Intraepithelial γδ T-lymphocytes can be stained and quantitated reliably in FFPE duodenal biopsies. The results showed excellent specificity and sensitivity for celiac disease. The new IHC method of detection of γδ-IELs is a promising addition to the routine histopathologic assessment methodology of celiac disease.
Published: 2020

47. T06.02.7 SAFETY AND LONG TERM OUTCOME OF SELF EXPANDIBLE METALLIC STENT AS BRIDGE-TO-SURGERY FOR OCCLUSIVE COLORECTAL CANCER

Author: A. Di Leo, Giuseppe Losurdo, R. Lovero, R.F. La Fortezza, M. Principi, Fulvio Spirito, M. Gentile, and Angelo Andriulli
Subjects: medicine.medical_specialty, Hepatology, Colorectal cancer, business.industry, medicine.medical_treatment, Occlusive, Gastroenterology, Stent, medicine.disease, Outcome (game theory), Surgery, Term (time), medicine, Bridge to surgery, business
Published: 2020

48. Genetic determinants of telomere length and risk of pancreatic cancer: a PANDoRA study

Author: Claudio Pasquali, Raffaele Pezzilli, Katarina Cuk, Krzysztof Jamroziak, Gabriele Capurso, Pavel Vodicka, Timothy J. Key, Giulia Martina Cavestro, Kai Uwe Saum, Yogesh K. Vashist, Oliver Strobel, Martin Lovecek, H. Bas Bueno-de-Mesquita, Andrea Szentesi, Ofure Obazee, Angelo Andriulli, Andrea Mambrini, Cosimo Sperti, Kay-Tee Khaw, Rita T. Lawlor, Jörg Kaiser, Federico Canzian, Hanneke W. M. van Laarhoven, Livia Archibugi, Renata Talar-Wojnarowska, Martina Matarazzi, Jakob R. Izbicki, Gianfranco Delle Fave, Daniele Campa, Felice Pirozzi, Francesca Federici, Carlo Federico Zambon, Anna Katharina König, Thilo Hackert, Péter Hegyi, Chiara Valsuani, Stefano Landi, Hermann Brenner, Laimas Virginijus Jonaitis, Beatrice Mohelnikova-Duchonova, Franco Bambi, Domenica Gioffreda, Rudolf Kaaks, Niccola Funel, Pavel Soucek, Juozas Kupcinskas, Ludmila Vodickova, Daniela Basso, Maarten F. Bijlsma, William Greenhalf, Francesca Tavano, and Verena Katzke
Subjects: Oncology, medicine.medical_specialty, Pancreatic disease, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Gastroenterology, Cancer, Single-nucleotide polymorphism, medicine.disease, Telomere, Continuous variable, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Pancreatic cancer, Mendelian randomization, medicine, SNP, 030211 gastroenterology & hepatology, business
Abstract: Telomere deregulation is a hallmark of cancer. Telomere length measured in lymphocytes (LTL) has been shown to be a risk marker for several cancers. For pancreatic ductal adenocarcinoma (PDAC) consensus is lacking whether risk is associated with long or short telomeres. Mendelian randomization approaches have shown that a score built from SNPs associated with LTL could be used as a robust risk marker. We explored this approach in a large scale study within the PANcreatic Disease ReseArch (PANDoRA) consortium. We analyzed 10 SNPs (ZNF676-rs409627, TERT-rs2736100, CTC1-rs3027234, DHX35-rs6028466, PXK-rs6772228, NAF1-rs7675998, ZNF208-rs8105767, OBFC1-rs9420907, ACYP2-rs11125529 and TERC-rs10936599) alone and combined in a LTL genetic score ("teloscore", which explains 2.2% of the telomere variability) in relation to PDAC risk in 2,374 cases and 4,326 controls. We identified several associations with PDAC risk, among which the strongest were with the TERT-rs2736100 SNP (OR = 1.54; 95%CI 1.35-1.76; p = 1.54x10-10 ) and a novel one with the NAF1-rs7675998 SNP (OR = 0.80; 95%CI 0.73-0.88; p = 1.87x10-6 , ptrend = 3.27x10-7 ). The association of short LTL, measured by the teloscore, with PDAC risk reached genome-wide significance (p = 2.98x10-9 for highest vs. lowest quintile; p = 1.82x10-10 as a continuous variable). In conclusion, we present a novel genome-wide candidate SNP for PDAC risk (TERT-rs2736100), a completely new signal (NAF1-rs7675998) approaching genome-wide significance and we report a strong association between the teloscore and risk of pancreatic cancer, suggesting that telomeres are a potential risk factor for pancreatic cancer. This article is protected by copyright. All rights reserved.
Published: 2018

49. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome

Author: Giuseppe Mazzella, Martina Felder, Giovanna Fattovich, G.B. Gaeta, A. Smedile, Massimo Fasano, Maria Rosa Valvano, Antonio Massimo Ippolito, Michele Milella, Teresa Santantonio, Angelo Andriulli, Filomena Morisco, R. Granata, Pietro Gatti, V. Di Marco, Mario Angelico, Andriulli, A, Morisco, Filomena, Ippolito, A. M, Di Marco, V, Valvano, M. R, Angelico, M, Fattovich, G, Granata, Rocco, Smedile, A, Milella, Marina, Felder, M, Gaeta, G. B, Gatti, P, Fasano, M, Mazzella, G, Santantonio, T., Morisco, F, Granata, R, Milella, M, Gaeta, Giovanni Battista, Andriulli A., Morisco F., Ippolito A.M., Di Marco V., Valvano M.R., Angelico M., Fattovich G., Granata R., Smedile A., Milella M., Felder M., Gaeta G.B., Gatti P., Fasano M., Mazzella G., Santantonio T., Andriulli, A., Morisco, F., Ippolito, A. M., Di Marco, V., Valvano, M. R., Angelico, M., Fattovich, G., Granata, R., Smedile, A., Milella, M., Felder, M., Gaeta, G. B., Gatti, P., Fasano, M., and Mazzella, G.
Subjects: Liver Cirrhosis, Male, Multivariate analysis, clinical features, Chronic HCV liver disease, Type 2 diabetes, Sex Factor, Hepacivirus, Gastroenterology, Polyethylene Glycol, Polyethylene Glycols, therapeutic outcome, chemistry.chemical_compound, Genotype, Age Factor, Settore MED/12 - Gastroenterologia, Sustained virologic response, Age Factors, virus diseases, HCV genotype 1 subtypes (1a and 1b), Hepatitis C, Recombinant Protein, Middle Aged, Recombinant Proteins, Treatment Outcome, Interferon, RNA, Viral, Female, HCV subtype, Human, Adult, medicine.medical_specialty, Liver Cirrhosi, Alpha interferon, macromolecular substances, Interferon alpha-2, Antiviral Agents, Sex Factors, Diabetes mellitus, Internal medicine, Ribavirin, medicine, Humans, Peg-interferon and ribavirin, Antiviral Agent, Hepaciviru, Hepatology, business.industry, Interleukins, technology, industry, and agriculture, Interferon-alpha, Interleukin, Hepatitis C, Chronic, medicine.disease, Virology, digestive system diseases, chemistry, Diabetes Mellitus, Type 2, HCV genotype, Interferons, hepatitis C, business
Abstract: Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13%) with subtype 1a and 1,074 (87%) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients with HCV-1a versus HCV-1b were young age, male gender, no F4 fibrosis, and no diabetes. SVR was achieved by 37% of patients with subtype 1b and 45% of those with subtype 1a, a nonsignificant difference of 8% (p=0.069). In patients with subtype 1a, predictors of SVR were IL28B CC (OR 5.78, CI 1.98–16.83), RVR (OR 4.18, CI 1.66–10.55), female gender (OR 2.83, CI 1.83–6.78), and HCVRNA (OR 0.55, CI 0.32–0.96). In patients with subtype 1b, the ranking of predictors was levels RVR (OR 6.49, CI 4.32–9.73), IL28B CC (OR 3.32, CI 2.15–4.58), γGT (OR 1.59, CI 0.14–2.22), HCVRNA (OR 0.61, CI 0.47–0.79), and age (OR 0.01, CI 0.02–0.42).Conclusion: In Italy HCV-1 subtype 1a prevails in young male patients with less advanced liver damage, findings that imply a more recent spreading of the infection with this viral strain. The two HCV-1 subtypes appear equally responsive to Peg-IFN/RIBA, with IL28B genotyping and monitoring of RVR mostly influencing the therapeutic response.
Published: 2015

50. P.03.17 PERCUTANEOUS ULTRASOUND FINE NEEDLE BIOPSY IN SOLID PANCREATIC LESIONS

Author: Francesco Perri, Fabrizio Bossa, Giuseppe Losurdo, K. Sitajolo, Fulvia Terracciano, Angelo Andriulli, and Antonio Massimo Ippolito
Subjects: medicine.medical_specialty, Percutaneous, Hepatology, business.industry, Ultrasound, Gastroenterology, Medicine, Radiology, business, Fine needle biopsy
Published: 2019

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

413 results on '"Andriulli, A"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources